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Abstract 
PURPOSE: Cationic liposomes are non-viral vectors studied for cancer gene therapy. However, 
liposomal-mediated transfection levels in the liver are significantly lower than those observed in 
other organs. In this study, we evaluated the feasibility of coating liposomal preparations with a 
liver targeting ligand derived from malaria circumsporozoite (CS) region II+ peptide. 
METHODS: A novel derivative of region II+ peptide was designed and synthesized. It was 
studied for its liver targeting potential for liposomal-mediated gene delivery. Liposomes-peptide 
association: the targeting ligand was either added in the hydration step of liposomes preparation 
or in the fmal stage after extrusion. The technique of density gradient airfuge was used to 
evaluate liposome-peptide association. Liposomes-HepG2 interactions: cells were incubated 
with liposomes labeled with 3H cholesterol. Cells were then lysed and radioactivity was 
measured. Transfection Experiment: PCMV53 plasmid containing the tumor suppressor gene 
p53 was used for the preparation of the liposomal complexes. The transfection experiments were 
executed using liver cancer cell lines. Western blotting analysis was performed to determine p53 
expression. 
RESULTS: more than 70 % of the targeting peptide was associated with the cationic liposomes 
when the former was added in the hydration step. The percentage however dropped to less than 
40% if peptide addition was performed in the final stage. No difference was observed between 
liposomal and liposomal-peptide preparations after incubation with HepG2 cells. Similar results 
were obtained by western blotting analysis. 
CONCLUSION: the peptide was successfully incorporated with the liposomal formula. Its 
binding specificity however was not achieved by our methodology. 
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1. Introduction 
1.1 Gene therapy: 
Gene therapy includes the treatment of both genetically based and infectious 
diseases by introducing genetic materials which have therapeutic effects (Anderson FW 
1998; Crystal RG 1995; Miller AD 1992). In its simplest terms, a wild type gene (which 
is non-functional in the cell leading to disease development) is introduced into the 
somatic cell lacking this gene to restore the normal gene function in this cell. Many gene 
therapy strategies, however, utilize genes to destroy specific cells. Such strategy is 
widely encountered in cancer gene therapy (Fillat C et al., 2003; Zeh HJ, and Bartlett DL 
2002). Another gene therapy strategy is found in the diseases of the nervous system 
where the genetic basis is very complicated or not well understood. Therapeutic genes in 
this case encode for a protein which is missing in the neuro-cells. The loss of 
dopaminergic neurons, for example, plays a major role in the development of Parkinson's 
disease (Lindvall 0 et al., 1990). Therefore, genes that can enhance dopamine 
production will have therapeutic effects (Latchman DC and Coffin RS, 2000). Genes can 
also boost the body's defense system against foreign infectious microorganisms. Gene 
therapy for human immunodeficiency virus (HIV), which relies on boosting T -cell 
immunity, for instance, has entered phase I clinical trails (Clayton J, 2002). 
During the past 15 years, intensive research in the area of gene therapy has 
embarked worldwide with the first approved gene therapy clinical trial in 1990 in which 
the adenosine deaminase (ADA) gene was transferred into T -cells of two children with 
severe combined immuno-deficiency (ADA-SCID) (Blaese RM et al., 1995). After a 
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decade, there are more than 400 clinical studies in gene therapy. Almost 70% of these 
studies are in the area of cancer gene therapy (Breyer Bet a/., 2001). 
1.2. Cancer gene therapy: 
Gene therapy for cancer is one of the most studied applications of gene therapy. 
Over 2,500,000 cancer patients died in the United States alone between the years of 
1976-1996 (Ries LAG eta/., 1999). The transformation of normal cells into neoplastic 
ones is associated with multi-mutational alterations at the genetic level in these cells 
(Bertram JS 2000). Therefore, gene therapy can provide a new treatment which may 
reduce the mortality rate among cancer patients, especially if combined with conventional 
therapy. Due to the complex nature of cancer, cancer gene therapy includes many 
therapeutic strategies. These strategies can be categorized into two main avenues: 
immunologic and molecular (Heo DS 2002; Brand K 2000). 
1.2.1. Immunologic approaches in cancer gene therapy: 
There are two aims for the immune system to encounter foreign antigens. One 
arm includes antibodies which are secreted by B cells after being activated through 
membrane immunoglobulin (B cell receptors) -antigen binding. Antibodies are soluble 
proteins that circulate in the blood to reach their targeted soluble antigens. On the other 
hand, T cells, the second arm of the immune system, do not secrete antibodies and 
interact directly with the antigen which can be a synthesized antigen presented at the cell 
surface through major histocompatibility complex (MHC) within a certain cell population 
3 
(e.g. cancer cells). T cells can then mediate multiple immune reactions including 
cytotoxic effects (Benjamini E et al., 2000). 
Cancer cells are immunogenic in nature with cancer antigens being intracellular 
molecules (Oettgen HF, and Old LJ 1999). Therefore, cellular immunity (T-cell 
mediated) is more prominent than humoral immunity (B-cell mediated) (Rosenberg SO et 
al., 1999). The regular immune response, however, is not enough to eradicate tumor 
cells. The ability of cancer cells to escape the immune system is related to the secretion 
of immunosuppressive factors (Cochran AJ et al., 2001), down-regulation of antigen 
expression (Kurnick JT et a!., 2001; Uyttenhove C et a!., 1983) or MHC molecules 
(Cabrera CM eta!., 2003; Hui K eta!., 1984), and the lack of co-stimulation (Pardoll DM 
1998; Galea-Lauri Jet a!., 1996). In fact, the antigen is presented by the tumor cell itself 
rather than the antigen presenting cells (APC) capable of co-stimulants secretion. 
Genetic immunotherapy can be utilized mainly to boost T -cell mediated immune 
response against cancer. 
One of the most frequently encountered genetic immunotherapy strategies 
involves the transfer of the genes of the immune-stimulant molecules such as cytokines. 
Intensive research has focused on the transfection with Interleukin-12 (IL-12) gene. 
Complete tumor regression in rat animal models was observed in hepatocellular 
carcinoma (HCC) and adenocarcinoma after successful IL-12 gene transfection into the 
cancer cells (Shi F eta!., 2002; Barajas M et al., 1996). The production of IL-12 by 
tumor cells mediates the immune response by the activation of many components in the 
immune system, in particular cytotoxic T lymphocytes (CTL) and natural killer (NK) 
cells (Saudemont A eta/., 2002; Caruso Metal., 1996). 
4 
Another genetic immunotherapy approach includes the in vitro manipulation of 
APC cells to enable them of active tumor antigen presentation. Dendritic cells (DC) are 
the most powerful APC cells. Engineered DC, for example, expressing a.-fetoprotien 
(AFP), HCC antigen, was able to provoke a strong immune response against the 
cancerous cells (Vollmer CM Jr et a/., 1999). Acute leukemic cells can also boost body 
immunity after being modified ex vivo into functional APC cells (Stripecke R et a/., 
2002). These strategies of in vitro manipulation are very efficient in treating minimal 
disease status observed after conventional chemo- and radio- therapies (i.e. cell vaccines). 
Direct genetic vaccination by the antigen-encoding genes can also induce the 
desired immune reaction against cancer cells. When injected by subcutaneous or 
intramuscular routes, DNA enters local cells (fibroblasts or myocytes) which can then 
produce and secret the antigen. APC will capture the new antigen and migrate to the 
lymphoid organs initiating the desired immune response (Ribas A eta/., 2000). AFP-
expressing tumors, for instance, were rejected by at least 60% of tested mice after being 
vaccinated with AFP-expressing gene. The life span in the treated animals was also 
significantly prolonged (Hanke P et al., 2002; Grimm CF et a/., 2000). Similarly, 
immunization of monkeys by carcino-embryonic antigen gene resulted in both humoral 
and lympho- proliferative immune responses (Conry RM eta/., 1999). 
1.2.2. Molecular approaches in cancer gene therapy: 
Up-regulation or down-regulation of some genes is the basis of tumor initiation 
and progression. The underlying mechanism of gene dysfunction includes many 
mutations on the genetic level. Many genes are involved in the transformation from 
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normal cell state to neoplastic state (Bertram JS 2000). The two gene groups believed to 
be mainly involved in cancer development are oncogenes and tumor suppressor genes. 
Oncogenes are growth promoting while tumor suppressor genes are growth inhibiting. 
Therefore, the later group and antioncogenes can be used in cancer therapy. In either 
case, the aim is to induce cell cycle arrest or better apoptosis (programmed cell death) in 
cancer cells. In addition to antioncogenes and tumor suppressor genes, suicide genes 
which also target cancer cells on the molecular levels is another molecular approaches in 
cancer gene therapy. 
1.2.2.1 Suicide genes: 
This strategy relies on the conversion of non-toxic substances (prodrugs) into 
physiologically active agents by means of non-mammalians enzymes. These enzymes 
were over-expressed in the neoplastic cells as a result of a successful transfection with 
their genes (Kim D et al., 2002; Mullen CA 1994). 
One of the most investigated suicide gene/prodrug systems is the herpes simplex 
vtrus thymidine kinase (HSV-tk)/ ganciclovir (GCV) system. HSV-tk is a herpetic 
enzyme that catalyzes the phosphorylation of nucleoside analogs such as the antiviral 
drug GCV (Fillat C et al., 2003; Dubowchik GM, and Walker MA 1999). The 
phosphorylated GCV mediates the killing of cancer cells via apoptotic (Wei SJ et al., 
1998; Hamel Wet al., 1996) and non apoptotic mechanisms (Kwon GY et al., 2003; Link 
CJ Jr eta/., 1997). 
One of the powerful features in these systems is the bystander effect. It is the 
mechanism by which the toxic metabolites are transferred from transduced cells to 
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neighboring cancerous cells via gap junctions and/ or apoptotic vesicles described below 
(Tanaka T et al., 2001; Freeman SM et al., 1993). It has been shown that the treatment 
with GCV for cancer cells with as few as 10% of the cells expressing the HSV -tk gene in 
vitro and 50% in vivo will lead to the same degree of cell death and tumor regression as 
that obtained with 100% cell transfection (Freeman SM et al., 1993; Takamiya Yet al., 
1993; Culver KW et al., 1992). 
Gap junctions or metabolic cooperation are cylindrical structures in the cellular 
membrane which link the cytoplasm of two adjunct cells. The main structure protein of 
gap junctions is Connexine32 (Cx32) (Ladish H et al., 2000). These cellular 
communicating units enable cells to transfer ionic and low molecular weight substances 
(i.e. < 2000 Da) between each other (Ladish H et al., 2000). The relationship between 
gap junctions and HSV-tkl CGV system is well established (Asklund T et al., 2003; 
Nicholas TW et al., 2003; Marconi Petal., 2000; Touraine RL et al., 1998). 
On the other hand, apoptosis is characterized by chromatin condensation, cell 
shrinkage, and the formation of apoptotic vesicles (apoptotic bodies) (Gschwind M and 
Huber G 1997) which are phagocytosed by adjunct cells. Apoptotic bodies were 
detected, for example, in HSV -tk negative colon cancer cells which were co-cultured 
with HSV-tk positive cells after GCV treatment (Freeman SM et al., 1993). 
This two step approach in cancer gene therapy, however, may affect the 
surrounding non-cancerous cells. Normal tissue damage was reported when rat hepatoma 
was treated with the HSV -tk/GCV system (Bustos M et al., 2000). 
In addition to HSV -tk/ GCV system, there are many other systems which are 
under investigation. These systems include, but not limited to, cytosine deaminase 
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(CD)/5-fluorocytosine (Yoshimura I et al., 2001; Li Z et al., 1997), cytochrome P450/ 
cyclophosphamide (Chen Let al., 1996; Wei MX et al., 1995), and carboxypeptidase/ 4-
[2-chloroethyl2-mesyloxyethel-0-amino] bensoyl-L-glutamic acid (CMDA) (Marais Ret 
al., 1996). 
1.2.2.2 Antioncogenes: 
The biological activity of oncogenes can be modulated and suppressed either on 
the RNA or DNA levels. Oligonucleotides are short nucleic acid segments that can bind 
to a specific sequence of the RNA (antisense oligonucleotides) or the DNA (antigene 
oligonucleotides) (Zhang WW, and Roth JA, 1994; Helene C, 1994). 
1.2.2.2.1 Antisense oligonucleotides: 
Antisense oligonucleotides bind to mRNA through Waston- Crick base pairing 
inhibiting the translation step of protein synthesis (Kibler-Herzog L et al., 1990). One of 
the most prominent oncogenes is bcl-2 gene, a prototypical inhibitor of apoptosis (Gross 
A et al., 1999). Over-expression of bcl-2 also increases resistance to chemo- and radio-
therapies in cancer cells (Reed J 1999). Expression of bcl-2 in vitro was significantly 
reduced after treatment with the liposomal solutions of the antisense oligonucleotide 
03139 (Hu Q et al., 2002; Duggan BJ et al., 2001). The intravenous infusion of the short 
oligonucleotide 03139 in patients with solid tumors, however, did not show antitumor 
effects (Morris MJ et al., 2001). In contrast, the combination with chemotherapy 
revealed encouraging therapeutic results for leukemic patients (Marcucci G eta/., 2003). 
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Other important targets for antisense therapy are c-myc (Potter M, and Marcu KB 
1997) and ras family oncogenes (Scharovsky OG et al., 2000). For example, retardation 
in cell growth rate was observed in melanoma cells treated with antisense oligonucleotide 
targeting the c-myc gene (Chana JS et al., 2002). In vivo treatment showed significant 
reduction in tumor growth in adenocarcinoma-implanted rats only when combined with 
the chemotherapeutic agent Carboplatin which was not effective when used alone 
(Walker TL et al., 2002). Oncogenes seem to play a central role in cancer resistance 
against chemotherapy. 
It is also possible to include cleavage capable fragment in the oligonucleotides 
(i.e. ribozymes) (James HA 1999). This strategy will lead to the destruction of the 
targeted RNA. Point mutation in codon 12 of the K-ras oncogene was utilized 
successfully to design a site-specific antisense ribozyme (Kijima H, and Scanlon K.J 
2000). Apoptosis and tumor growth suppression were observed both in vitro and in vivo 
when colon cancer cells were treated with the K-ras antisense (Tokunaga T et al., 2000). 
1.2.2.2.2 Antigene oligonucleotieds: 
Antigene oligonucleotieds bind to the DNA through Hoogsteen hydrogen bonding 
forming a non-functional triple helical structure (Helene C et al., 1992). In this strategy, 
gene expression is blocked at the transcription stage. The main benefit of this approach 
over the antisense strategy is the limited targets for the therapeutic oligonucleotieds (two 
targets per cell versus hundreds to thousands of mRNA for the antisense 
oligonucleotieds). For example, the combined radiotherapy, via 99mtechnetium (99~c), 
and bcl-2 antigene treatment was illustrated in vitro through the use of 99mTc-conjugated 
9 
bcl-2 antigene resulting in successful transcriptional cessation of the bcl-2 gene (Shen C 
et al., 2003). 
In addition, the combination of more than one antigen can result in synergistic 
effects. Dual treatment with c-myc and c-erbB2 (also known as HER/neu) antigenes, for 
example, increased cell growth inhibition in ovarian cancer cells by almost 20 % more 
than individual antigene treatments (about 60% cell growth inhibition) (Fei R, and 
Shaoyang L 2002). 
1.2.2.3. Tumor suppressor genes: 
Tumor suppressor genes constrain unusual cell proliferation (Weinberg RA, 
1991). These genes are capable of apoptosis and cell cycle arrest induction in the 
malignant cells (Opalka Bet a/., 2002). The main representative gene of this family is 
the p53 gene which is responsible for the detection of DNA damage followed by repair 
initiation or apoptosis induction (Sager R, 1989). Mutational alterations in the p53 gene 
occur in almost 40% of all tumors (Greenblatt MS et a/., 1994). Despite that wild type 
p53 (wt p53) belongs to tumor suppressor gene family, some of its mutant forms can act 
as oncogenes (Marshall CJ, 1991; Lane DP and Benchimol S, 1990). Therefore, 
successful transfection of the wt p53 into cancerous cells will have therapeutic outcomes. 
It is well documented that p53 gene induces apoptosis and cell cycle arrest in cultured 
cells (Sauter ER et al., 2002; Roy I et al., 2002; Mitry RR et a/., 1997). Similarly, tumor 
growth inhibition and tumor regression in animal models were observed after p53 
transfection (Dolivet Get al., 2002; Anderson SC eta/., 1998; Hsiao Metal., 1997). 
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p53 treatment has found its way into clinical stages. Intratumoral injections of 
adenovirus mediated transfection of p53 (Ad-p53) for 28 patients diagnosed with non-
small cell lung cancer (NSCLC) resulted in disease stabilisation in 16 patients (64%) and 
more than 50% tumour size reduction in two patients (Swisher SG et al., 1999). More 
promising outcomes were reported when Ad-p53 treatment was combined with 
chemotherapy (Cisplatin) (Nemunaitis J et al., 2000) or radiation (Swisher SG et al., 
2003). In the later combination, no viable tumor was observed in 63% of patients after 
three month of the completion of the therapy. 
Another tumor suppresser gene which has been also tested for clinical trials is the 
EJA gene (Hortobagyi GN et al., 2001). EJA gene is efficient in treating cancer cells that 
over-express the HER!neu oncogene such as ovarian and breast cancers (Ueno NT et al., 
2001; Wang SC and Hung MC 2001 ). Many other apoptotic genes such as p 16, p21, p27, 
E2F-1, FHIT, E4 and PTEN are currently investigated in animal experimental settings 
(Opalka B et al., 2002). 
1.2.2.4. Other molecular approaches in cancer gene therapy: 
Cancer tissue proliferation is associated with vasculature growth from existing 
blood vessels (i.e. angiogenesis) (Folkman J 1990). Angiogenesis provides cancerous 
cells with the necessary nutrients; therefore, interfering with this process in the tumor can 
produce therapeutic effects. The main targets for anti-angiogenesis cancer therapy 
includes inhibiting angiogenic inducers (namely vascular endothelial growth factor 
(VEGF) and angiopoietine) or introducing angiogenic inhibitors such as angiostatine, 
endostatine, IL-12, and p53 (Chen QR et al., 2001). For example, tumor growth of 
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implanted HCC cells in athymic mice was proportional to the percentage of cells 
transfected with angiostatin gene. No tumor was detected when 90-100% of cells were 
transfected with the antiangiogenesis gene (Ishikawa H et al., 2003). It was also 
illustrated that significant tumor regression was achieved when only 5% of human breast 
cancer cells were transduced with the apoptotic gene p53 (Xu M et al., 1997). This 
tumor regression was, however, associated with 60% reduction in the number of the 
blood vessels (i.e. anti-angiogenesis effect). The main advantages of this cancer therapy 
strategy are the easy accessibility to the endothelial cells of the blood vessels and its 
applicability to different cancer types. 
Another cancer gene therapy approach includes the prevention of toxic side 
effects, mainly myelosuppression, of antineoplastic agents. This can be achieved by 
transfering the drug resistance genes such as multiple drug resistance gene-1 (MDR-1) 
into the hematopoietic progenitors (Licht T and Peschel C 2002; Koc ON et al., 1999). 
MDR-1 gene encodes for P-glycoprotein, a cell membran transporter which effluxes 
many hydrophobic and amphipathic substances (Gottesman MM eta/., 1995). The main 
advantage of this strategy is overcoming the dose-limiting toxicity of traditional 
chemotherapy. 
1.3. Gene delivery systems: 
The main objective in gene therapy is successful in vivo transfer of the genetic 
materials to the targeted tissues. The aim from the delivery system varies according to 
the application. For example, prolonged and sustained expression is needed for treating 
diseases related to one gene dysfunction like hypercholesterolemia while short period of 
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gene expression is sufficient for most cancer gene therapy strategies. Despite that naked 
DNA was used successfully when injected directly into the tumor (Shi F et al., 2002; 
Walther Wet al., 2002) or as DNA vaccines (Hanke P et al., 2002; Conry RM et al., 
1998), it is highly prone to tissue clearance and totally inefficient for systematic delivery 
(Kawabata K et al., 1995). 
Gene therapy vehicles can be categorized into two groups: biological and non-
biological systems. Each group has its own advantages and limitations. Biological 
carriers are viruses which were naturally evolved to infect cells and transfer their genetic 
materials into the host cells. Viral vectors used in gene therapy were modified to 
eliminate their pathogenicity and retain their high efficiency in gene transfer. They are, 
however, difficult to produce and toxic (in particular immunogenic), as well as having a 
limitation in terms of the size of the inserted gene (Cusack JC Jr and Tanabe KK 2002). 
These limitations are not encountered in the less efficient non-viral gene carriers such as 
liposomes. In either case, selected modifications that can produce safe, efficient and 
targetable gene carriers are desirable. 
1.3.1. Biological gene delivery systems (viral vectors): 
1.3.1.1 Retrovirus: 
Retrovirus carriers are developed by replacing the vital viral genes with 
therapeutic ones. The ability of retroviral vectors to successfully deliver foreign genetic 
materials was first described in 1981 (Wei CM et al., 1981; Shimotohno K and Temin 
HM 1981 ). Retroviruses are small RNA viruses with DNA intermediates, that integrates 
into the host genome producing the viral proteins (gag, pol, and env) which are removed 
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wh~H d~v~lo~iiig the gene delivery earner. Most of these viruses infed acHvely dividing 
cells during mitosis (Lewis PF and Emerman M 1994; Miller DG et al., 1990). Despite 
that this feature might protect the normal tissues and provide natural targeting to the 
tumor, all tumors contain non-dividing cells in the resting phase G0. These cells will not 
be affected by retrieval-mediated gene transfer. Lentiviruses such as HIV and their 
vectors can, however, infect non-proliferating cells (Buchschacher GL Jr and Wong-Staal 
F 2000; Lewis PF and Emerman M 1994). Transfection efficiency was 10 times higher 
in ovarian cancer cells when lentiviruses were used in comparison to retroviral vectors 
(lndraccolo S et al., 2002). The usage of lentiviruses, however, has a major drawback 
because of the original serious clinical consequences of these viruses. 
In this context, the new retroviral vectors, namely replication-competent 
retroviruses, were developed and engineered to replicate specifically in the targeted 
neoplastic tissues; thus, increasing the vectors' non-toxic transduction ability (Solly SK et 
al., 2003; Logg CR et al., 2002). 
1.3.1.2 Adenovirus: 
Adenoviruses are double-stranded DNA viruses that can infect both dividing and 
non-dividing cells (Li Q et al., 1993; Quantin Bet al., 1992). The wild type viruses can 
cause benign respiratory infections in humans (Doerfler W 2000). The defective-
competent adenoviral vectors were first generated by substituting the viral El gene with a 
therapeutic gene. More efficient gene carriers were obtained by altering more genes in 
the viral genome such as the E2 gene (Engelhardt JF et al., 1994). The removal of the 
whole coding sequence of the viral genome resulted in better gene carriers in terms of 
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their capacity {Harrington KJ et al., 2001). Transfection with adenoviruses is transient 
since the DNA genome does not permanently integrate into the host cell genetic material 
{Kelly TJ Jr 1984). Therefore, repetitive administration of the adenoviral vectors is 
needed to obtain the desired therapeutic outcomes. 
Adenoviral vectors have been widely used for cancer therapy applications 
{Swisher SG et al., 2003; Roy I et al., 2002; Anderson SC et al., 1998). It has been 
shown that adenovirus-mediated gene transfer is more efficient in immuno-deficient 
animals (Ragot T et al., 1993). Both cellular and humoral immune responses limit the in 
vivo efficiency of these gene carriers (Mack CA et al., 1997; Yang Y et al., 1994). 
Therefore, co-administration of immunosuppressive agents may increase the adenoviral 
transduction ability. Such strategy may not be attractive for cancer therapy since the 
immune response can be utilized for tumor destruction. On the other hand, it was 
hypothesized that systemic immunity can reduce the toxic effects of these vectors 
{Bramson JL et al., 1997) which accounts for the first reported death in clinical gene 
therapy trials (Raper SE et al., 2002). Surprisingly, the pre-immunization of mice 
bearing cancerous tissues with the null vector increased the mortality rate between high-
dose treated animals in comparison with non-immunized animals. Positive results (less 
toxic effects), however, were observed for moderate dosing (Vlachaki MT et al., 2002). 
It was suggested that adenovirus/ antibody immune complex at high doses will induce 
complement activation which may lead substantially to systemic lethal inflammatory 
reactions {which does not occur in moderate dosing). 
Similar to retrovirus vectors, conditionally replicative adenoviruses were also 
successfully developed for selective cancer gene therapy (Heise C et al., 2000; Rodriguez 
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R et a/., 1997). In one study, adenoviruses were developed to replicate selectively in wt 
p53- deficient tumor cells. This was achieved by gene deletion of the EJB viral protein 
which binds naturally to wt p53 allowing viral propagation in wt p53 cells (Bischoff JR et 
al., 1996). 
1.3.1.3. Herpes simplex virus (HSV): 
HSV family naturally infects humans in the eye or the oral and vaginal mucosa 
causing lytic curable effects. During their life cycle, they infect the sensory nerve ending 
and migrate to the neuronal cells resulting in a latent infection (Corey L, and Spear PG 
1986). This feature was utilized to deliver genes effectively to brain tumors (Parker JN et 
a/., 2000). HSV vectors are produced by eliminating the sequence of some of the viral 
proteins expressed early in the infection such as !CPO, ICP4, ICP27 and ICP22 (Wu N et 
al., 1996; Marconi P et al., 1996). These proteins can trigger the production of other 
essential viral components. 
The large linear double strand genome of HSV virus (about 150 kb), which is 
almost 15 and 4 times bigger than that of lentiviruses and adenoviruses respectively, can 
be replaced by almost 40 kb of foreign genes, ranking at the top of viral vectors' capacity 
(Latchman DS 2001). This capacity was utilized successfully to simultaneously deliver 
multiple genes using one vector. Despite that both HSV-tk and CD suicide genes, for 
example, were delivered successfully to malignant glioma in vivo using single HSV 
vector, their single treatments were superior to the combined delivery (Moriuchi S et al., 
2002). 
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On the other hand, both the original pathologic and latent infectious nature of 
these viruses can limit their therapeutic applications. In the case of cancer gene therapy, 
latency is not a major concern since temporary active gene expression can produce the 
desired destruction effects on cancer cells. 
1.3.1.4. Adeno- associated virus (AA V): 
AAVs are single stranded DNA viruses. They encode for two viral proteins 
namely Rep and Cap which are removed in the defective vectors used in gene therapy 
(Jain KK 1998). Similar to adenoviruses, AA Vs can infect both dividing and non-
dividing cells. Their DNA, however, integrates into the host cell genome in a similar 
way to the retroviruses. AA V vectors cause little toxicity since their wild type version 
does not cause any pathologic effects in humans and they integrate specifically into 
chromosome 19 of the human genome (Samulski RJ et al., 1991). Such specificity will 
reduce the risks of insertional mutagenesis encountered in retroviral mediated gene 
transfer. In addition, the site of integration does not encode any important gene. 
The main drawback in this system, however, is the need for helper viruses 
(adenoviruses or HSV) for AA V production (Buller RM et al., 1981; Janik JE et al., 
1989). This may result in contaminated AA V vectors during preparation. This 
disadvantage was overcome by inducing viral replication through genotoxic stimuli such 
as heat shock, chemicals or irradiation (Y akinoglu AO et al., 1988). In fact, AA V 
mediated gene transduction was significantly enhanced when combined with UV and 
gamma radiation treatments (Alexander IE et al., 1996; Alexander IE et al 1994). In 
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addition to replication difficulties, the capacity of these vectors is very limited (less than 
5 kb of DNA) (Cusack JC Jr, and Tanabe KK 2002). 
Despite that AA V vectors were used in cancer gene therapy (Ponnazhagan S et 
a/., 2001 ), it has been shown that other viral systems such as adenoviruses possess better 
transfection ability (Vermeij Jet a/., 2001). 
1.3.1.5. Pox virus (Vaccina Virus): 
These viruses were used as vaccines which eradicated smallpox virus worldwide. 
They are double stranded DNA viruses that can infect both dividing and non-dividing 
cells. Similar to HSV, they have a large genome (about 186 kb) such that they can 
accommodate up to 25 kb transgenic sequence (Smith GLand Moss B 1983). 
Because of the landmark success in recombinant vaccination via poxviruses, 
which can induce T -cell mediated immune reaction against infectious and malignant 
diseases (Gomella LG eta/., 2001; Paoletti E 1996), they were successfully tested for 
cytokine gene delivery against cancer in preclinical studies (Qin H et al., 2001; Peplinski 
GR et al., 1995). Such strategy can produce synergistic immunological effects. 
Moreover, the anti-tumor effects and survival rates between tumor bearing mice were 
significantly enhanced when IL-2 and IL-12 were delivered simultaneously using single 
vaccina viral vector along with the tumor antigen (Kaufinan HL et al., 2002). The 
previous study also demonstrates the feasibility of delivering multiple genes using single 
vaccina viral carrier. This feature in viral-mediated gene delivery systems is only possible 
with vaccina and HSV vectors. 
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The long history in the usage of these vectors in vaccination, their low toxicity, 
and high capacity for foreign DNA make them excellent carriers for gene delivery. 
1.3.2. Non- biological gene delivery systems (non-viral vectors): 
All non-viral systems are cationic in nature. They interact with negatively 
charged DNA through electrostatic interactions. The total charge, however, should 
maintain a net positive value. This will enable the carrier of efficiently interacting with 
the negatively charged cell membranes and internalizes into the cell which occurs mainly 
through the endocytosis pathway (behr JP 1994). 
1.3.2.1. Cationic polymers: 
This group of gene carriers includes any synthetic cationic polymer (at 
physiological pH) that can be combined with DNA to form a particulate complex, 
polyplex, capable of gene transfer into the targeted cells. Since they are synthetic 
compounds, many modifications such as molecular weight and ligand attachment can be 
easily achieved. The most widely studied polymers for gene therapy include poly-L-
lysine (PLL) and poly(ethylenimine) (PEl). 
1.3.2.1.1. Poly(ethylenimine) (PEl): 
PEl was used in gene delivery more recently than PLL. It is usually branched 
with every third amino nitrogen atom being protonated such that PLL has a buffer 
capacity virtually at any pH value (proton sponge) (Boussif 0 eta/., 1995). This feature 
and PEl's ability to destabilize Lysosomal membranes enables PEl polyplexes to 
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efficiently escape the degradation within the acidic endosomal environment (Kichler A et 
al., 2001; Klemm AR et al., 1998). 
Many factors affect the efficiency/ cytotoxicity profile of PEl polyplexes (and 
almost any non-viral vector) such as molecular weight, degree of branching, ionic 
strength of the solution, zeta potential and particle size (Kunath K eta!., 2003; Kircheis R 
et al., 1999). One study, for instance, showed that low molecular weight (10 kDa), 
moderately branched polymer resulted in efficient delivery with low toxicity in 
comparison with commercial high molecular weight PEl (Fischer D et al., 1999). 
Another study demonstrated that linear PEl (22 kDa) was more efficient in both salt and 
salt-free buffers than branched polymers (25 and 800 kDa) (Wightman Let al., 2001). 
Lethal side effects in mice, however, were observed when the linear PEl (22 kDa) 
polyplex was injected intravenously within its therapeutic window (Chollet P et al., 
2002). Therefore, more studies are needed to produce optimum PEl carriers with respect 
to efficiency/ toxicity behavior. 
The nature of these polymers enables the researchers to successfully introduce 
targeting ligands and/ or polyethylene glycol (PEG) (that produces sterically stabilized 
gene carriers) to their surfaces. Pegylated PEl polyplexes, for instance, were linked to 
tumor specific ligand transferrin, an asialoglycoprotein, and then applied intravenously, 
resulting in five fold increase in the transfection efficiency with lower toxicity in 
comparison with pegylated (transferrin-free) PEl polyplexes (Kircheis Ret al., 1999). 
20 
1.3.2.1.2. Poly-L-lysine (PLL): 
PLL is one of the first cationic polymers employed for gene transfer (Wu GY, and 
Wu CH 1987). They are linear polypeptides with the amino acid lysine as the repeat unit; 
thus, they posses a biodegradable nature. This property is very useful for in vivo 
applications. PLL polyplexes are, however, rapidly bound to plasma proteins and cleared 
from the circulation (Ward CM et al., 2001; Dash PR et al., 1999). In addition, 
successful transfection requires co-application of chloroquine, a lysosomotropic agent, 
which reduces the lysosomal degradation of lipoplexes (Pouton CW et al., 1998; 
Shewring L et al., 1997). The exact mechanism in which chloroquine acts is not well 
understood. Chloroquine can be substituted with fusogenic peptides which undergo pH-
related conformational changes perturbing the lysosomal/ endosomal membranes, thus 
the DNA is successfully delivered into the cell cytoplasm (Lee H et al., 2002; Wagner E 
et al., 1992). In fact, PLL has poor transfection ability when applied alone or without 
modifications (Brown MD et al., 2000; Pouton CW et al., 1998). One popular 
modification that can increase both the transfection ability and the circulation half-life of 
these vectors is coating with PEG (Ward CM et al., 2002; Lee H et al., 2002). Targeting 
ligands were also linked to the polymer chain (even in early studies) resulting in 
enhanced transfection (Suh Wet al., 2001; Wu GY, and Wu CH 1987). A common 
efficient strategy implies the addition ofboth PEG and a targeting ligand to PLL polymer 
to optimize transfection (Faraasen S eta/., 2003; Nah JW eta/., 2002). Another approach 
can create the desirable 'proton sponge' effect similar to that of PEl polyplexes by 
introducing histidine residues to PLL backbone (Pichon C et al., 2001 ). Histidylated PLL 
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showed better transfection efficiency than PLL/ chloroquine mixture (Midoux P and 
Monsigny M 1999). 
Many PLL polymers with different molecular weights were tested and evaluated 
for gene transfer (Mannisto Metal., 2002; Ward CM et al., 2001; Nishikawa Metal., 
1998). It has been shown that DNA condensation and transfection efficiency increased 
with high molecular weight PLL, which was also associated with undesirable high 
toxicity (Wolfert MA et al., 1999). The creation of amphiphilic PLL, by linking both 
PEG and palmitoyl groups to the polymer, reduced toxicity without compromising the 
gene delivery efficiency (Brown MD et al., 2000). 
1.3.2.1.3. Other polymeric delivery systems: 
Many other cationic polymers such as chitosans (a biodegradable linear 
aminopolysacharides) (Koping-Hoggard M et al., 2003; Lee M et al., 2001) and 
dendimers (highly branched polyamidoamine) (Vincent Let al., 2003; Bielinska AU et 
al., 2000) were tested for gene transfer. A novel polycations known as reducible 
polycations (RPC) prepared by oxidative polycondensation of the peptide Cys-Lys10-Cys 
resulted in enhanced transfection in comparison with PLL (Read ML et al., 2003). It is 
believed that cellular reduction of disulfide bonds of these vectors will facilitate gene 
delivery and reduce cytotoxicity. Despite the low number of clinical trials which utilize 
polymer-mediated gene transfer in gene therapy, it is expected that this area will continue 
to grow and expand in the near future. 
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1.3.2.2. Cationic peptides: 
Cationic peptides employed for gene transfer are amphiphilic peptides which can 
undergo conformational changes in acidic environments escaping the endosomal 
/lysosomal pathways. They contain the positively charged amino acids (i.e. histdine, 
lysine, and/ or arginine) such that they can effectively condense DNA. The a-helical 
KALA peptide (derived from the influenza HA-2 subunit which enables the virus to 
infuse into the cell membrane) is one of the early cationic peptides used successfully for 
gene delivery in cultured cells (Wyman TB et al., 1997). Despite that 7 positively 
charged amino acids (lysine) exist in the (30 AA) KALA peptide, it was demonstrated 
that only 4 cationic AA (arginine) in other a-helical peptide (total16 AA) were sufficient 
to condense DNA and deliver it to the cytoplasm (Niidome T et al., 1999). The 
efficiency of the peptide vector will also depend on the hydrophobic portion that plays a 
major role in aggregation and endosomal escape (Haines AM et al., 2001; Ohmori Net 
al., 1998). The relationship between peptide aggregation and efficient gene delivery is 
not well understood. DNA release into the cytoplasm can also be enhanced by the 
introduction of cysteine moieties into the peptide backbone, resulting in the formation of 
reducible disulfide bonds within the DNA/peptide complex (McKenzie DL et al., 2000). 
The reduction occurs after the internalization of the delivery complex. 
Similar to other vectors, receptor-mediated gene transfer can be achieved through 
ligand attachment (Niidome T et al., 2000). 
Peptide gene carriers have been mainly explored in vitro (Kim HH et al., 2003; 
Niidome T et al., 1999; Plank C et al., 1999; Wyman TB et al., 1997). Their in vivo 
behavior is still under investigation. In a recent study, transfection with peptide vectors 
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by intravenous administration in mice was reported and occurred mainly in the lungs. It 
was, however, 10 to 40 folds less efficient than liposomes and PEl vectors (Rittner K et 
al., 2002). 
1.3.2.3. Cationic Lipids (liposomes): 
Since their introduction as gene carriers in 1987 (Feigner PL et al., 1987), 
liposomes have become one of the most studied non-viral vectors. They include a group 
of positively charged lipids at the physiological pH. As with other non-viral vectors, they 
interact with the negatively charged DNA through electrostatic attractions. Cationic 
lipids were used mainly in the form of liposomes. More recently, however, cationic lipid 
emulsions have been described and evaluated as possible non-viral gene carriers (Yi SW 
et al., 2000; Choi BY et al., 2002). 
1.3.2.3.1. Liposoms and liposomes/ DNA complex structures: 
Cationic lipids are amphiphilic molecules composed of one or two fatty acid side 
chains (acyl) or alkyl, a linker, and hydrophilic amino group. Figure 1 shows an example 
of cationic lipid DOTAP (1,2-dioleoyl-3-trimethylammonium-propane) which consists of 
two unsaturated diacyl side chains ( oleoyl), ester linker and propyl ammonium group 
(Lasic DD 1997). Other lipids may contain different linkers such as the more stable ether 
linkages e.g. DOTMA (N [1-(2,3-dioleyloxy) propyl] - N, N, N-trimethylammonium 
chloride) (Feigner PL et al., 1987). The hydrophobic part can also be cholesterol-derived 
moieties (Gao H, and Hui KM 2001). Multivalent cationic lipids (which can condense 
DNA more efficiently than monovalent lipids) were synthesized and successfully 
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evaluated for liposomal-mediated gene transfer (Ewert K et al., 2002; Behr JP et al., 
1989). 
Hydrophobic Chain (olyeol) Ester Linker 
I N-
1+ 
0 Hydrophilic amine group 
0 
Figure 1: Schematic representation of the cationic lipid DOTAP. The hydrophobic part (olyel), the ester 
linker, and the hydrophilic portion are presented. Most other cationic lipids share the same general 
structure. 
In aqueous media, cationic lipids are assembled into a bilayer vesicular-like 
structure (liposomes). Liposomes are first arranged into multilamellar vesicles. 
Unilamellar vesicles can then be obtained by sonication (Huang CH 1969), detergent 
removal (Jiskoot Wet al., 1986) or extrusion through porous membranes (Hope MJ et al., 
1985; Mayer LD et al., 1986). The liposomes/DNA complex is usually termed a 
lipoplex. Based on freeze-fracture electron micrographs and x-ray diffraction studies, it 
was suggested that DNA is sandwiched between many liposomal particles (Radler JO et 
al., 1997; Sternberg B et al., 1994). This structure is in agreement with the increase of 
particle size after the addition of DNA to cationic liposomes (Almofti MR et al., 2003b ). 
Negatively-charged DNA will neutralize cationic liposomes resulting in aggregation and 
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continuous fusion with time while DNA being entrapped during this process. Because of 
poor stability (i.e. continuous aggregation), lipoplexes are usually administered directly 
after their formation. Many physical factors influence stability, complex formation and 
transfection efficiency of lipoplexes such as particle size, zeta potential, DNA/liposomes 
ratio and ionic strength of the medium (Almofti MR et al., 2003b; Pedroso de Lima MC 
et al., 2001; Ross PC et al., 1999). Producing the favorable, stable, small lipoplex 
particles was obtained with the development of the novel liposomal formulation LPD 
(liposomes/ Protamine/ DNA) which will be discussed later. 
1.3.2.3.2. Structure/ activity relationship: 
Despite the numerous studies that focus on the possible relationship between 
cationic lipid structure/ composition and lipoplex transfection activity, solid conclusions 
are rarely obtained. This is mainly due to the complex factors affecting gene transfer, 
even different cell lines, for example, will produce different behavior with the same 
lipoplex formulations (Zou Y et al., 2000; Balasubramaniam RP et al., 1996). More 
important, the correlation between in vitro and in vivo experiments is not always obtained 
(Gorman CM et al., 1997; Lee ER et al, 1996; Solodin I et al., 1995). Therefore, it is 
expected that empirical findings will remain the main source for structure/ activity 
relationships. 
It has, however, been proven that the addition of neutral lipids (colipids) will 
increase the transfection ability of lipoplexes both in vitro and in vivo. The most 
common colipids are cholesterol (Chol) (Liu Yet al., 1997; Bennett MJ et al., 1995) and 
dioleylphosphatidylethanolamine (DOPE) (Hui SW et al., 1996; Farhood H et al., 1995). 
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While the former is more efficient in vivo, the later enhances in vitro lipoplex transfection 
(Simberg D et al., 2001; LiS eta/., 1998; Wang Jet a/., 1998; Hong K eta/., 1997). It 
was demonstrated that lipoplexes enter cells through endocytosis and fusion pathways 
(Almofti MR et a/., 2003b; Farhood H et a/., 1995). Neutral lipids facilitate 
conformational changes from a bilayer structure into hexagonal arrangements at the 
endosomallevel (Hafez IM et al., 2001; Litzinger DC, and Huang L 1992). This change 
will trigger the release of the encapsulated DNA into the cytoplasm before reaching the 
destructive lysosomal environment. 
1.3.2.3.3. Liposomes/ Protamine/ DNA (LPD): 
Protamine is an arginine-rich peptide which can condense negatively-charged 
DNA before being complexed with cationic lipids. The polycation PLL (which is less 
efficient) was also tested for LPD preparation in early studies (Gao X and Huang L 
1996). Liposomes will interact with condensed DNA resulting in lipid rearrangement 
and the formation of compact liposomes/ DNA complex (LPD) (LiS and Huang L 1999). 
Figure 2 compares proposed complex structures between LPD and conventional 
lipoplexes. 
DOTAP and DC-Chol (3~ [N-(N', N' -dimethylaminoethane) carbamoyl] 
cholesterol) were used for the preparation of LPD with the most common co-lipids: 
cholesterol and DOPE respectively (Tan Yet a/., 2002). Particle size distribution ofLPD 
ranged from 100-250 nm which is almost three to five times less than conventional 
lipoplexes (Ueno NT eta/., 2002; Sorgi FLeta/., 1997; Gao X and Huang L 1996). 
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Figure 2: Schematic comparison between LPD and lipoplex particles. In Fig.2A: DNA 
is nutrlaized and condensed with the protamine before the formation of the complex LPD. 
In Fig.2B: DNA is sandwiched between liposomal particles forming the 'conventional' 
lipoplex. 
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Stability with no compromise in the transfection ability was maintained for 4 months 
when LPD was stored at 4°C or at room temperature after lyophylization (freeze-drying 
or spray-drying) (Seville PC et al., 2002; Li B et al., 2000). Both in vitro and in vivo 
studies showed superiority of LPD mediated gene transfer over conventional liposomes 
(Li S et al., 1998; Sorgi FL et al., 1997). It is believed that the small size of LPD will 
facilitate endocytosis and increase the in vivo circulating half life. Like other non-
modified liposomes, LPD tends to accumulate preferably in the lungs after injection from 
the tail vein of a mouse (Li S et al., 1998; Li S and Huang L 1997). In addition to the 
lungs, reporter gene expression, however, was also detected in other organs such as the 
kidney, the spleen and the liver (Li S et al., 1998; . Li S and Huang L 1997). Reporter 
genes encode usually for readily detected proteins such that the transfection ability can be 
easily monitored and evaluated. 
For therapeutic applications, iv administration of DOTAP: Chol LPD carrying 
tumor suppressor genes Rb or EJA in cancer animal models resulted in apoptosis 
induction, tumor size reduction, and life span increase in the treated animals (Ueno NT et 
al., 2002; Nikitin A Y et al., 1999). As expected, antitumoral synergistic effects were 
obtained when EJA LPD treatment was combined with the chemotherapeutic agent 
paclitaxel (Ueno NT et al., 2002). These studies demonstrate the possibility of effective 
IV gene carrier administration, whereas intratumoral application (or as close as possible 
to the tumor) are more effective in most studies of various gene delivery systems. LPD 
composed of DC-Choll DOPE was also tested in clinical settings when two children with 
Canavan disease (a fatal CNS disease characterised by spongy degradation of cerebral 
30 
white matter) were treated with ASPA gene via intracerebral application; both subjects 
showed some clinical improvements (Leone P et al., 2000) 
1.3.2.3.4. Targeted liposomes: 
The same strategies applied at anionic liposomes to develop tissue-specific 
formulations are also encountered in targeted cationic liposomes. More emphasis on 
tumor-specific liposomes and liposomes/ ligand attachment techniques are discussed 
below. The two main strategies in developing targeted liposomes are achieved by 
attaching monoclonal antibody (mAb) (i.e. immunoliposomes) or tissue specific ligand to 
the surface of the liposomes. 
1.3.2.3.4.1. Immunoliposomes: 
Antibodies are soluble proteins produced by B cells of the immune system to bind 
specifically to the antigens mediating its destruction directly or with the help of other 
immune system components. They consists of two major parts, Fab (fragment antigen 
binding) fragments responsible for antigen recognition and Fe (fragment crystallizable) 
fragments which play a role in the biological activity (Benjamini E et al., 2000). 
Immunoliposomes are widely studied because of their relative ease of preparation 
and high specificity. Antibodies or Fab fragments were first linked to liposomes in early 
eighties by attaching them directly to the lipids (Leserman LD et al., 1980; Heath TD et 
al., 1980). Because of their short half lives, immunoliposomes are mostly used in long 
circulating peglated liposomes (Bendas G 2001). There are two methods in attaching 
antibodies to the surface of the peglated vesicles, either through the terminal end of PEG 
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chain (ShiN et al., 2001; Allen TM et al., 1995) or directly to the lipids (Klibanov AL et 
al., 1991). The former attachment methodology is extensively used and favored since the 
ligand will be away from the liposomal surface providing easy access to the antibodies. 
PEG chains will cause steric barriers when the mAb or Fab is attached to the lipids. It 
has been shown, for instance, that PEG 2000 will mask the lipid-linked antibody less than 
the longer PEG 5000 (Mori A et al., 1991). In addition, a comparison between PEG-
linked and lipid-linked antibodies showed that efficient coupling was better achieved 
with the PEG chains (Hansen CB et al., 1995). While the coupling reaction to PEG is 
usually proceeded after the preparation of the liposomes, anchor lipid molecules are 
generally attached first to the antibody before being assembled into the liposoaml 
structure during preparation (in case of direct linkage of the antibody to the lipids). On 
the other hand, a novel simple preparation method for immunoliposomes were developed 
by transferring the lipid conjugated mAb or Fab micelles to preformed, drug loaded 
liposomes under specified conditions of temperature and pH (Allen TM et al., 2002; Iden 
DL, and Allen TM 2001; Ishida T et al., 1999). This method is referred to as post 
insertion technique. 
In cancer gene therapy, gene expression in tumors was significantly enhanced 
with immunoliposomes technology compared to conventional liposomes (Lee CH et al., 
2003; Kao GY et al., 1996). Life span of mice bearing aggressive brain tumor was, for 
instance, increased by 100% after treatment with epidermal growth factor receptor 
(EGFR) antisense mRNA delivered by intravenous injection of immunoliposomes 
(Zhang Y et al., 2002). 
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In all the above studies, antibodies were covalently linked to the liposomal 
surface. Non covalent linkages were, however, used by simple mixing of the antibody 
with the liposomal vesicles resulting in two to four fold increases in the transfection 
efficiency of the reporter gene in glioma cell line (Yoshida J and Mizuno M 1995; 
Mizuno M, and Yoshida J 1996). More efficient non-covalent linkages were obtained 
through avidin-biotin binding. Biotinated lipids were bound to strepavidin (contains four 
biotin binding sites) which was then attached to biotinated mAb by simple incubation 
(Hansen CB et al., 1995; Loughrey H et al., 1987). 
Immunogenicity is the main concern associated with immunoliposomes 
applications. This drawback was minimized by the usage of Fab subunits (instead of the 
whole antibodies) or the fully humanized mAb produced first in the mid eighties 
(Verhoeyen M et al., 1988; Jones PT et al., 1986). The linkage techniques of Fab 
fragments are identical to those applied on the complete mAb, covalently (LeeCH et al., 
2003; Heath TD et al., 1980) or non-covalently (Mizuno M, and Yoshida J 1996; 
Loughrey H et al., 1987). These liposomes/ ligand attachment methods are also 
applicable on all other peptides and proteins ligands. 
1.3.2.3.4.2. Ligand targeted liposomes: 
This group of targeted liposomes has the advantage of low immunogenicity in 
comparison with immunoliposomes. Ligands vary according to the targeted tissues. One 
popular target is the liver associated with many genetically based diseases such as 
hemophilia, lipoprotein receptor deficiency and a !-antitrypsin deficiency as well as liver 
cancer. Many receptors are expressed specifically on the surface of this organ namely 
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low density lipoprotein (LDL) and asialoglycoprotein receptors. Therefore, the 
discussion in this section will focus on liver targeted liposomes. The main challenge for 
successful liver targeting is to reach the parenchymal cells rather than being captured by 
kupffer cells. 
Asialoglycoprotein receptors (ASGP-R) are very specifically abundant on the 
mammalian parenchymal liver cells. Their major role is to clear glycoproteins and 
lipoproteins from the circulation. The receptor contains carbohydrate recognition domain 
which can bind to galactose derivatives (Wu J et al., 2002). 
Asialofetuin (AF) is a natural ligand for ASGP-R. It is a glycoprotein with 
several terminal galactose sugar chains (Spiro RG 1973). It was effectively incorporated 
into the liposomal surface by covalently attaching a hydrophobic moiety (palmitic acid) 
as an anchor among the lipids of the liposomal vesicles (AF-liposomes) (Hara T et al., 
1988; Tsuchiya S et al., 1986). AF-liposomal uptake by the liver in mice was increased 
11 times in comparison with non modified liposomes (Wu Jet al., 1998). Similarly, AF-
liposomal mediated transfection of the human alpha antitrypsin (hAA T) gene was 
significantly enhanced in comparison with regular liposomes. After one year of the 
treatment, hAAT mRNA in the liver was detected in all animals transfected with AF-
liposomes versus only 25 % with those treated with regular liposomes with more than 
4000 fold increase in case of AF-liposomes condition (Dasi Fetal., 2001). In this study, 
AF was covalently linked to an anchor lipid on the surface of preformed liposomes. AF, 
however, can induce immunogenic reaction. Therefore, simpler glycosylated liposomes 
were developed and evaluated for liver targeting (Kawakami S et al., 2002). 
Glycosylated cholesterol, for example, was synthesized and incorporated into the cationic 
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liposomal vesicles resulting m 10-fold mcrease of gene expresston m the liver 
(Kawakami S et a/., 2000). 
Liver cancer is another important target for gene delivery. HCC (hepatocellular 
carcinoma) is a leading cause for cancer related deaths worldwide (Bosch FX 1997). 
Gene therapy can provide a new approach to treat this fatal disease. In addition to the 
different specific receptors on the hepatocyte cells, there are some receptors which are 
over-expressed in hepatoma cells. One example is transferrin (TF) receptors which are 
also elevated in other malignant cells (Keer HN eta/., 1990). TF-liposomes will not only 
target the cancerous cells but it will also reduce non-desired transfection levels in the 
surrounding normal tissues. This feature can be exaggerated by hepatic arterial injection 
of TF-liposomes mediating DNA delivery (Seol JG et a/. , 2000). TF-liposomes 
complexes are usually prepared through charge-charge interactions by simple mixing and 
incubation (Li X eta/., 2003; Seki Metal., 2002; Seol JG eta/., 2000). Tumor growth 
was inhibited up to 70% in liver tumor xenografts after treatment with TF-liposomes 
containing the antiangiogenesis gene, endostatin (Li X eta/., 2003). Linkages to the PEG 
terminal end of pegylated liposomes were also used for TF-liposome preparations 
(Derycke AS, and De Witte P A 2002; Iinuma H eta/., 2002). 
1.4. Rational, research hypothesis, and objectives: 
Despite the many advantages of cationic liposomes as gene carriers over the viral 
vectors in terms of safety and unlimited DNA size, they have natural affinity towards the 
lungs (McLean JW eta/., 1997; Solodin I eta/., 1995). In this study, we investigated the 
possibility of coating cationic liposomes with a liver targeting ligand. We aimed to 
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deliver the apoptotic gene p53 specifically to liver cancer cells. Traditional therapies 
such as surgery, radiotherapy, chemotherapy, and/or liver transplantation have shown 
limited success on the survival rates of HCC patients (Okuda K et al., 1984). Tumor 
suppressor gene p53 can induce apoptosis and/or cell cycle arrest in cancerous cells 
lacking the wt p53 (Zou Y et al., 1998; Anderson SC et al., 1998). In liver cancer, 
mutational alterations occur in about 30-50% of the p53 gene (Greenblatt MS et al., 
1994; Tabor E 1994), thus successful transfection of the p53 gene to hepatic cells may 
have therapeutic effects. 
Our targeting ligand was derived from the malaria circumsporozoite (CS) surface 
protein. It has been illustrated that CS protein is responsible for directing the malaria 
parasite within minutes towards the liver after mosquito bite. The injection of CS protein 
into mice, for instance, resulted in direct homing of the protein into the liver (CeramiC et 
al., 1994). The protein also plays important role in the development of the sporozoite 
inside the cells (Frevert U et al., 1998). 
CS protein of the human Plasmodium falciparum (P. falciparum), for example, 
consists basically of three segments, theN-terminus region (containing region I peptide), 
repeat domain (37 NANP and 4 NVDP) and C-terminus region (containing region II+ 
peptide) (Dame JB et al., 1984) (Fig. 3). It has been proven that the two conserved 
peptide sequences (region I and region II +) in the CS protein play a critical role in 
receptor recognition on the surface of the hepatic cells (Ying Petal., 1997; Chatterjee S 
et al., 1995; Aley SB et al., 1986). In our study, we explored the possibility of utilizing 
region II + peptide for developing liver specific liposomal formulation. 
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1.4.1. Malaria region II+ peptide: 
Region II+ peptide is located on the carboxyl terminus region of CS protein. It 
consists of 18 amino acids conserved among rodent, monkey and human malaria 
parasites (see fig. 3). Our ligand was derived from the human P. fa/ciparum CS protein. 
Region II+ initiates the binding of CS protein by interacting with heparan sulfate 
proteoglycans on the cell surface (Frevert U et al., 1993; Ying Petal., 1997). It has been 
shown that region II+ can totally inhibit CS protein from selective binding to hepatic 
cells (Sinnis P et a/., 1994; Cerami C et a/., 1992). The peptide has hydrophobic motif at 
its N-terminus EWSPCSVTCG with two cysteins. The sequence CSVTCG mediates cell 
adhesion and it is identical to adhesion domain of thrombospondin, a modular adhesive 
glycoprotein (Prater CA eta/., 1991; Lawler J and Hynes RO 1987). 
CS Protein 
Human P. falciparum 
Human P. vivax 
Monkey P. brasilianum 
Monkey P. knowwlesi 
Monkey P. malariae 
Monkey P. cynomolgi 
Rodent P. yoelii 
Rodent P. berghei 
Avian P. gallinaceum 
SVTCGNGIQVRIK. 
EWTPCSVTCGVGVRVRRR 
EWSPCSVTCGSG~ 
EWTPCSVTCGNGVRIRRK 
EWSPCSVTCGSGIRARRK 
EWSPCSVTCGKRVRMRRK 
EWSQCSVTCGSGVRVRKR 
EWSQCNVTCGSGIRVRKR 
EWTNCNVTCGKGIQAKIK 
Figure 3: Schematic representation of CS protein and region 
II +peptide between different malaria species. Amino acids 
that varies from the human P. Falciparum used in this study are 
balded. 
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The amino acid sequences were obtained from the following sources: 
P. falciparum (Caspers P et al .• 1989; de I a Cruz VF et al .• 1987); P. vivax (McCutchan TF 
et a/., 1985); P. brasi/ianum (Lal AA et al., 1988b); P. knowwlesi (Godson GN et al., 
1983); P. malariae (Lal AA et a/., 1988a); P. yoelii (Lal AA et a/., 1987); P. berghei 
(Eichinger DJ et al., 1986); P. cynomolgi (Galinski MR et a/., 1987); P. gallinaceum 
(McCutchan TF et a/., 1996). 
1.4.2. Modifications on malaria region II+ peptide: 
Fatty acid chains namely palmitate and myristate were linked to theN-terminus of 
region II + peptide. These fatty acids will serve as an anchor between the fatty acyl 
chains of the liposomes. This strategy was adopted for protein and glycoprotein ligand 
incorporation into the liposomal surface for selective targeting (Sliedregt LA et a/., 1999; 
Wu J et a/., 1998; Hughes BJ et al., 1989; Huang A et al., 1980). 
Two modified fatty acid linked region II+ peptides were used in this study to be 
incorporated into the lipid membranes of the liposomes. These peptides will be refered to 
as peptide I and peptide II (See fig. 4). Peptide I was linked to palmitic acid at its N-
terminus, while peptide II was linked to myrstic acid. Peptide I has an extension of 5 
amino acids derived from the original CS protein sequence at its C-terminus. We used 
the segment described by Cerami C et al., (1992) for specific targeting. It was shown 
later that this extension is not essential for the binding specificity of region II+ peptide 
(Sinnis P et al., 1994). Therefore, we tested the extension at the N-terminus for peptide 
II. The extension at theN-terminus was also derived from CS protein original sequence 
(de la Cruz VF et al., 1987). The later strategy may provide a spacer between the lipid 
layers and the ligand such that the ligand will be more accessible for binding. Tyrosine 
was added at the N-terminus of peptide I versus C-terminal of peptide II. Tyrosine will 
enable the radio labeling of the peptide with 125I for detection and quantification purposes. 
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Palmitic Acid 0 
Y EWSPCSVTCGNGIQVRIKPGSAN 
Peptide I 
Myristic Acid 
NSLSTEWSPCSVTCGNGIQVRIKY 
Peptide II 
Figure 4: Structures of peptides I and II of malaria CS region II+ peptide used in this 
study. 
1.4.3. Statement of research objective: 
The aim of this study is to coat the novel cationic liposomal formulation LPD 
(bearing the p53 gene for liver cancer treatment) with the malaria region II+ peptide for 
hepatocyte selective targeting. We investigated the feasibility of in vitro liver targeting 
as prestudy for any possible future in vivo investigations. 
39 
2. Materials and methods 
2.1. Chemicals: 
All chemicals were purchased from Sigma-Aldrish (St. Louis, MO, USA) unless 
otherwise indicated. 
2.2. Tissue culture and the choice of the cell lines: 
Hepatoma cell lines Hep G2, MeA RH7777 and Hep 3B were used in this study. 
Both human HepG2 and rat MeA RH7777 were maintained in Dulbecco's modified 
Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 1% (penicillin 
/streptomycin), 4 mM L-glutamine, 0.11 giL sodium pyruvate and 4.5 giL glucose. 
Human Hep 3B with integrated hepatitis B virus (Aden et al., 1979) were cultured in 
minimum essential medium Eagle (EMEM) with 2 mM L-glutamine, 1.5 giL sodium 
bicarbonate, 0.1 mM non-essential amino acids, and 1.0 mM sodium pyruvate, 10% fetal 
bovine serum, and 1% (penicillin/streptomycin). Cells were incubated in humidified 
incubator at 37° C in 5% C02• All cell lines were obtained from American Type Culture 
Collection (ATCC), Manassas, VA, USA. 
The Hep G2 cell line was used in this study since binding affinity of malaria CS 
protein and region II+ peptide to this hepatoma cell line is well-documented (Rathore D 
et al., 2002; Suarez JE et al., 2001; Sinnis P et al., 1994; Cerami C et al., 1992). 
However, the Hep G2 cell line naturally expresses the human wt p53 protein, and 
therefore is not a suitable model for p53 transfection studies. Detection of p53 in Hep G2 
cells after successful transfection with wt p53 gene will not differ from non-treated cells 
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since the levels of the protein is controlled within the cells. In contrast, both MeA RH 
7777 and Hep 3B cell lines do not contain the human wt p53 in their genome. MeA RH 
7777 cell line contains mutated rodentp53 that can not be detected by human monoclonal 
antibody used in this study (Anderson SC et a/., 1998). Human Hep 3B has deletion in 
p53 gene (Puisieux A eta/., 1993; Bressac Bet a/., 1990). Therefore, both cell lines were 
used as model for the in vitro transfection experiments. 
2.3. Targeting peptide solution: 
The two modified forms of region II+ peptide (as discussed earlier) were 
synthesized according to our suggestion (Genemed Synthesis Inc, San Francisco, CA, 
USA) with a purity of 80%. Peptides were dissolved in a minimum volume of dimethyl 
sulfoxide (DMSO) and then diluted with deionized water or dextrose 5% (DSW %) 
solution such that the fmal percentage of DMSO did not exceed 2% of the total volume. 
Under these conditions, no aggregates were observed under microscopic examination 
(Wilovert®; 1 OOx magnification). 
2.4. Preparation of 125 I peptide: 
Tyrosine was added to the N terminus of peptide I and the C terminus of peptide 
II to enable us to radiolabel the peptides with 125I for subsequent qualitative analysis of 
peptide/liposomes complexation and peptide/ HepG2 cells interactions. IODO-BEADS® 
iodination reagent (Pierce Inc., pockford, IL, USA) was used to perform the labeling as 
instructed by the manufacturer. The bead was first washed three times with 300 J .tl of 
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D5W % solution. It was then dried on filter paper and placed in Eppendo~ tubes 
(Fisher Scientific, Pittsburg, PA, USA) containing 100 J • .tl (D5W %). Ten to fifteen J.ll of 
65.5 Ci/mmol Na1251 (NEN products, Boston, MA, USA) were added to the tube and 
allowed to react for about 5 min. Peptide solution was then added to the tube and the 
reaction was allowed to proceed for 5 min. The reaction was stopped by removing the 
solution from the tube. The beads were washed two time with 200 J.ll (D5W %). To 
remove the free iodine, 1251 peptide solution was dialyzed against 2 liters of D5W% 
solution at 4° C using molecular porous dialysis tubes (Spectra/Por mwCo: 2000, Los 
Angeles, CA, USA). Dialysis solution was changed several times till the radioactivity of 
1 ml of the dialysis solution was less than 1000 cpm measured with Gamma counter 
(1272 Clinigamma LKB Wallac, Turk:u, Finland). 1251-labeled peptide was stored at 4° C 
for future use. The specific radio-activity of the peptide is specified for each individual 
experiment. Peptide concentration was measured by Bio-Rad DC protein assay kit 
(Hercules, CA, USA), using micro-plate assay. 
2.5. Protein assay: 
Protein assays were performed by Lowry method (Lowry et al., 1951) using the 
DC protein assay kit (Bio-Rad, Hercules, CA, USA). Briefly, working reagent A' was 
formed by combining twenty microliter of surfactant solution (reagent S) with 1 ml of 
alkaline copper tartarate solution (reagent A). Within the range of 0.2 mg/ml to 1.37 
mg/ml, six dilutions of the protein standard (bovine serum albumin BSA 1.3 7 mg/ml; 
Bio-Rad) were prepared. Five microliters of standards and samples were pipeted in 96-
well microliter plate. Twenty-five microliters of reagent A' were then added to each well 
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followed by 200 J.ll of dilute folin reagent (reagent B). Mixtures were allowed to stand at 
room temperature for almost 15 min. Absorbencies were then measured 
spectrophotometrically at a wavelength of 630 nm by Microplate reader (Bio-Rad Model 
550, Japan). The sensitivity of this assay is 0.2 mg/ml. 
For micro-microplate assay (suggested by the manufacturer) with higher 
sensitivity (5J.t.g/ml), volumes of sample (or standard), reagent A' and reagent B were 20, 
10, 80 J.ll respectively. Reagent S was not used when samples did not contain surface-
active ingredient. 
2.6 Liposomes preparation: 
At a molar ratio of 1:1, DOTAP (Avanti Polar Lipids, Inc., Albaster, AL, USA), a 
positively charged phospholipid, and cholesterol (Chol) were dissolved in chloroform 
(HPLC grade). The organic solvent was then evaporated in a round-bottomed flask under 
vacuum for at least 30 minutes or until a dry lipid film was formed at the bottom of the 
flask. The lipid film was then hydrated by deionized water or by an aqueous solution of 
the targeting peptide. In either case, the final concentration of DOT AP was 10 mg/ml in 
the lipid mixture. The hydration process was then continued by rotating first for 45 
minutes at 50° C followed by 10 minutes at 30° C. The mixture was allowed to stand at 
room temperature overnight under argon atmosphere. Unilamellar vesicles (UL V) were 
prepared by the extrusion method using a mini extruder (A vanti polar lipids, Inc., 
Albaster, AL, USA) as described by others (MacDonald RC et al., 1991; Templeton NS 
et a/., 1997). The lipid solution was first sonicated at low frequency for 5 minutes at 50° 
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C, kept in hot water bath ( 50° C) for 1 0 minutes and then sequentially extruded through 
polycarbonate membrane with the following pore sizes 1, 0.6, 0.2, 0.1 J..tm. Liposomes 
were used within 24 hours. 
For radioactive experiments, 3H radio-labeled cholesterol eH-Chol) (NEN 
products, Boston, MA, USA) was included in a percentage of 0.5 or 1% molar of the total 
cholesterol used in liposomal preparations. 
2. 7. Liposomall peptide complexes preparation: 
Two methods were adapted for the inclusion of the targeting peptide into the 
liposomal formulas. 
a) Liposomes/ peptide complex I: the peptide was added to the preparation after 
extrusion (the final stage). 
b) Liposomes/ peptide complex II: the peptide was incorporated during the 
hydration step of liposomal preparation. The final concentration of the 
peptide in liposome solutions was 0.5 or 1 f.lg/f.ll. 
2.8. Assessment of liposomes/ peptide association: 
The technique of sucrose gradient airfuge was applied to test liposomes/ peptide 
complex formation. Airfugation was performed as described (Rivnay B and Metzger H, 
1983) with some modifications. Stock solutions of sucrose (ultracentrifugation grade, 
Fisher, FairLawn, NJ, USA) 5, 10, 20, 25, 30, 60% (w/w) were prepared and checked by 
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refractive index measurements using Abbe-type refractometer (American Optical Inc., 
Buffalo, NY, USA). Airfuge tubes (ultra-clear 5 x 20 mm, Beckman Instruments Inc., 
Palo Alto, CA, USA} were weighted before the initiation of the centrifugation such that 
each pair matched and were within 1-2 mg difference to reduce rotor wobbling during the 
acceleration and deceleration. Four non-continuous gradients containing 45 J.t.l 25%, 40 
J.t.l 20%, 25 J.t.l 10%, and 30 J.t.l 5% of sucrose solutions were prepared unless otherwise 
indicated. In order to prevent turbulence and solution mixing during gradient 
preparation, tubes were placed on dry ice then sucrose solutions were sequentially added. 
This methodology allowed us to prepare six tubes in less than 15 minutes. Gradient was 
thawed at room temperature and 50 J.t.l of the sample was applied at the bottom with 
hamilton syringe. Twenty five f..ll of the samples were first diluted with the same volume 
of 60% of sucrose solution. 
The following Samples were produced: liposomes/ no peptide, peptide/ no 
liposomes, liposomes/ peptide complex I, and liposomes/ peptide complex II (1 J.t.g/J.t.l). 
The fixed angle rotor A-100/30 designed for Beckman Airfuge used in this study 
(Beckman ®, Palo Alo, CA, USA). 
Since the centrifuge was not designed to run the experiment at 4° C, 
centrifugation was carried out at room temperature at top speed (approximately 167,000 
g) for 60 minutes. Each tube was fractioned 25 f..ll from the top to the bottom of the tube 
with minimum insertion of the pipettor tip in the gradient. The last fraction was always 
less than 25 f..ll. 
One-mole percent of 3H-Chol and 0.4 % (w/w) of 125I peptide (specific activity 30 
cpm/ ng) were added to detected liposomes and ligand respectively. Counting was 
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performed in a Gamma counter (1272 Clinigamma LKB Wallac). 3H was counted in 
liquid scintillation (LS) counter (Beckman LS 5000 TD, fullerton, CA, USA) with 3H 
channel set to 0-400 KeV. 1251 interference with the 3H count in the LS machine was less 
than 1% in this experimental design. The only exception was liposomes/ peptide 
complex II in which suitable correction was established via a standard curve of 125 I count 
in LS vs. the counts in gamma counter to exclude 1251 contribution in the sample when LS 
is used. 
Sucrose gradient was run with no samples to check the density gradient pattern. 
2.9. Liposomes/ protamine/ DNA (LPD) preparation: 
PCMV53 plasmid containing the human wild type p53 gene (wt p53) was used 
for the preparation of LPD complexes. p53 plasmid was a gift from Dr. Pater lab, Basic 
Science, faculty of Medicine, Memorial University. In a ratio that was optimized by 
others (Li S eta/., 1998): 1J.Lg DNA: 0.6 J.Lg protamine sulfate: 12 nmol DOTAP-Chol 
liposomes., DOTAP-Cholliposomes were first mixed with protamine before adding the 
plasmid. The mixture was allowed to stand at room temperature for at least 20 minutes 
before either starting the transfection or adding the targeting peptide. 
2.10. LPD/ Peptide complex preparations: 
For liposomes/ peptide complexes, two methods were used for the preparation of 
the LPD/ peptide complexes: 
a) The peptide was included in the formulation at the final stage. In this method, various 
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amounts of the peptide ranging from 0.1-10 J.tg were added to LPD formulation. The 
LPD/ peptide complexes were incubated at room temperature for 20 minutes before the 
initiation of transfection. This complex will be referred to as LPD/ peptide complex I. 
b) The peptide was incorporated during the hydration step of liposomal preparation such 
that peptide concentration was 1 J.tg/J.tl. This method resulted in the following ratio of the 
formulation components: 1 J.tg DNA: 0.6 J.tg protamine: 12 nmol DOTAP: Chol (1:1) 
liposomes: 0.8 J.tg peptide. This complex will be referred to as LPD/ peptide complex II. 
Similar procedure and methodology were used to prepare lipoplex/ peptide 
complexes (i.e. no protamine). 
2.11. Cell transfection: 
The MCA RH 7777 rat hepatoma and human hepatoma Hep 3B cell lines were 
used as a model since human wt p53 is not expressed in these cell lines. About 3 x 103 
cells were seeded per well in 24-well plates. After about 48 hours, 80-90% cell 
confluence was reached. Cells were washed with phosphate buffered saline (PBS) (KCl 
2.67 mM, KH2P04 1.47 mM, NaCl 138 mM and Na2HP04.1H20 8.10 mM) and then 
incubated with 200 J.tl of serum free medium containing LPD or LPD/ peptide complexes. 
The transfection was terminated after six hours by replacing the transfecting medium 
with the full serum medium. All transfections were performed at 37° C in the presence of 
5 %C02. 
Protein purification was performed after 48 hours from the initiation of the 
experiment. Cells were washed twice with ice-cold PBS then lysed with 75 J.tl extraction 
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buffer [50 mM Tris.HCl pH 8.0, 150 mM NaCl, 0.02% sodium azide, 1% Igepal CA-630, 
0.1% sodium dodecyl sulfate (SDS), 0.5% sodium deoxycholate, 0.1 mglml 
phenylmethylsulfonyle fluoride (PMSF) and 0.01 mglml aprotinin] for 30 minutes and 
centrifuged at 12,000 g at 4° C for 10 min. The supernatant was then transferred to 
another micro-centrifuge tube and stored at -80° C. Protein concentration in each sample 
was determined by Bio-Rad DC Lowry protein assay kit. 
The expression of p53 protein was evaluated by western blotting analysis. Equal 
amounts of lysate (usually 10 J..lg of proteins) were boiled for 5 min in SDS-
polyacrylamide gel electrophoresis (PAGE) loading buffer (200 mM Tris'HCl pH 6.8, 4% 
SDS, 0.2% bromophenol blue, 20% glycerol). Samples were then loaded on SDS-PAGE 
gel and run at 200 Volts using mini-protein II electrophoresis cell (Bio-Rad) until 
bromophenol blue reach the bottom of the gel (about 45 min). The running gel was 
composed of 8-12 % acrylamide mix, 375 mM Tris'HCl (pH 8.8), 0.1 SDS, 0.1% 
ammonium persulfate, and 6 J..ll of N,N,N',N',- tetramethylethylenediamine (TEMED) 
(Bio-Rad, Richmond, CA, USA). The staking gel was prepared with 5% acrylamide mix, 
125 mM Tris'HCl pH 6.8, 0.1% SDS, 0.1% ammonium persulfate and 5 J..ll ofTEMED. 
After electrophoresis, the gel was incubated in Towbin gel transfer buffer (25 mM 
Tris base, 192 mM glycine, 20% methanol) for 15-30 min at room temperature. The 
proteins were transferred onto hybond enhanced-chemiluminescence nitrocelluse 
membrane (Pharmacia Biotech., Uppsala, Sweden) using electrophoretic transfer cell 
(mini trans-Blot®, Bio Rad, Hercules, CA, USA). Transfer was performed at 4° C for 
two hours at voltage of 100 volt. Following transfer, the non-specific binding sites on the 
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membrane were blocked with 5% fat free milk in Tris-buffered saline-Tween: TBS-T (20 
mM Tris base pH 7.6, 137 mM NaCl, 1M hydrochloric acid, and 0.1 %Tween) for 1 hr 
at room temperature with gentle shaking. The human wt p53 was probed by incubating 
monoclonal anti p53 antibody (NCL-p53-D07) (Novocustra Laboratories Ltd, Newcastle, 
UK) diluted in the blocking buffer (i.e. 5% fat free milk in TBS-T) overnight at 4° C with 
shaking. Membrane was then washed twice with TBS-T, incubated with horse-radish 
peroxidase conjugated secondary antibody diluted with blocking buffer for 1 hr at room 
temperature with agitation, and finally rinsed three times with TBS-T. The immunoblots 
were developed by the use of the enhanced chemiluminescence (ECL) detection system 
(Amersham Life Science, Inc., Buckinghamshire, UK) by exposing the membrane to 
ECL film as instructed by the manufacturer. 
~-Actin expression served as a control since its expression is not affected by p53 
treatment. Membranes were incubated at 50° C in stripping buffer (100 mM 2-
mercaptoethanol, 2% SDS, and 62.5 mM Tris.HCl pH 6. 7) with gentle agitation. After 
washing with TBS-T at room temperature, membranes were repro bed with anti-~-actin 
antibody (Sigma- Aldrish, Steinhelim, Germany) as described for p53 detection. 
2.12. Hemolytic activity: 
Hemolytic assay of the peptide were evaluated by incubating different 
concentrations of the peptide with freshly isolated rat erythrocytes such that the final 
concentration of the rat red blood cells (RBC) was 1 08 cells /ml. RBCs containing EDT A 
as anti-coagulant were first centrifuged at 1000 rpm for 10 minutes to remove the huffy 
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coat. Cells were then washed three times with D5W % solution and finally suspended in 
the same solution with a density of 2 x 108 cells/ ml. 
Prior to the assay, the peptide was dissolved first in DMSO then diluted with 
D5W % solution. Half milliliter of cell suspension was incubated with different 
concentrations of the peptide at 37° C for 30 minutes with gentle mixing. The mixture 
was then centrifuged for five minutes at 500 G. The supernatants were measured 
spectrophotometrically at a wavelength of 570 nm by Microplate reader (Bio-Rad Model 
550). One hundred percent hemolysis was obtained with 1% triton X 100. RBC exposed 
to D5W % solution were used as blank. To evaluate if DMSO interferes with the assay, 
hemolysis with D5W % solutions containing DMSO served as a control. 
2.13. Particle size measurement: 
Cationic liposomes were mixed with different amounts of the targeting peptide. 
After 20 min incubation at room temperature, samples were diluted 50 times with de-
ionized water. Particle size was measured by Delsa 440 Zeta sizer (Beckman Coulter, 
Miami, FL, USA) 
Similarly, liposomes /no peptide stored at 4° C under argon atmosphere were 
tested for any possible aggregation during the storage period. 
2.14. Negative stain electron microscopy (EM): 
Copper grids were floated on a droplet of liposomal formula for five minutes. The 
grid was dried for 10 min then it was stained with 10 % phosphotungstic acid for 5 
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minutes. Samples were viewed on JEOL 1200 EX electron microscopy, Japan. 
Photographs were taken at 20,000 magnification. 
2.15.HepG2-liposomes interaction: 
Cells were plated in 24-well plates in a density of 3 x 105 cells/ well. After 48 
hours, 90% cell confluence was obtained. Growth medium was then removed and cells 
were washed two times with PBS. One hundred nmoles of radiolabeled liposomes eH 
liposomes) were incubated with the cells in D5 W % solution. Incubation was performed 
at 4° C to minimize internalization. At 1, 2.5, 4, and 5 hours, cells were washed three 
times with ice cold PBS and then lysed with 250 J.Ll NaOH 0.1 M. Lysate (200 J.Ll) were 
then measured for radioactivity by liquid scintillation counter (Beckman LS 5000TD, 
Fullertan, CA, USA). Protein concentration was measured as described above. 
2.16. Binding of the targeting ligand to HepG2 cells: 
Hep G2 cells were seeded in 24-well plates in a density of 3 x 105 cells/well. 
After 90% confluence was reached, cells were washed three times with PBS, and fixed 
for 10 min with 4 % paraformaldehyde as described previously for CS and region II+ 
peptide/ Hep G2 binding studies (Sinnis P et al., 1996; Sinnis P et al., 1994; Cerami C et 
al., 1992). After washing with PBS three times, cells were blocked for 2 hrs with 1 % 
BSA in D5W % solution at 3 7° C. Cells were then rinsed twice with D5W % solution, 
incubated with different concentrations of peptide II for 1 hr at 3 7° C (concentration 
ranging from 0-1 mg/ml), washed three times with D5W % solution, incubated with 4 J.lg 
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of 1251 peptide II (specific activity 5.5 cpm/ng) for 1 hr at 37° C. Finally cells were rinsed 
three times with D5W % solution and lysed with 0.1 M NaOH solution. 
Two hundred ~l of lysate were then measured for radioactivity to assess the 
inhibition effects of the pre-incubation with cold region II+ peptide on the binding of 1251 
peptide using a gamma counter (Beckman Gamma 5500, Irvine, CA, USA). 
2.17 Mass spectroscopy: 
2.17 .1. Electrospray (ES) Ionization: 
Quadropole tandem mass spectroscopy (Micromass Quadro II Triple Quade 
MS/MS, Fisons, Manchester, UK) was used. Traces of the peptides were dissolved in 
50150 methanol/ dichloromethane. Ten ~l of the solution were introduced into the ES ion 
source. Peptide II was also tested in its aqueous solution (l~g/~l). 
2.17.2. Matrix-assisted laser desorption ionization- time of flight (MALDI-TO F): 
The dried droplet method was used in this technique (Beavis RC and Chait BT 
1991). The matrix was sinapic acid (SA) dissolved in 30% acetonitrile, 0.1% TFA (Tri-
flouroacetic acid) (10 mg/ml). SA solution was then purified from the undissolved 
particles through mild centrifugation. Peptide II (0.5 mg/ml) was diluted with the matrix 
and the dilution varied from Ill tol/4 (sample/ matrix). One micro-liter of this working 
solution was placed on the mass spectrometer's probe and air dried. The linear, time of 
flight MALDI-TOF system (Voyager-DE PRO, Applied Bio Systems, Foster City, CA, 
USA) was used to ionize the sample with N2laser beam (wavelength 337 nm). 
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2.18. Prediction of theoretical mass, isoelectric point (pi), and mean hydrophobicity: 
Theoretical mass and pi values for peptide segments were predicted using 
PeptideMass program available on line: http://www.expasy.org/tools/peptide-mass.html 
(Wilkins MR et al., 1997). 
Mean hydrophobicity was calculated via hydropathical scales: Kyte-Doolittle 
(Kyte J and Doolittle RF 1982), Eisenberg (Eisenberg D et al., 1982), and combined 
consensus scale (CCS) (Tossi A eta/., 2002). These values did not consider the fatty 
acid chains linked to the modified region II+ peptides. 
2.19. Statistical analysis: 
Student t-test was performed to evaluate the significant difference between 
various conditions. Significant level was set at P<0.05. Sigma plot 2001 version 7.00 
(SPSS Inc., Chicago, IL, USA) was used for the analysis. 
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3. Results 
3.1. Assessment of liposomes/ peptide association: 
The technique of density gradient ultracentrifugation is routinely employed for the 
separation of liposomes from associated or encapsulated substances (Nguyen XT eta/., 
2002; Dipali SR et al., 1996; Kurrle A et a/., 1990). Sample volume is usually in the 
range of milliliter for conventional ultracentrifugation. In our study, however, sample 
volume was in some cases less than 100 J,J.l. Therefore, an air-driven ultracentrifuge 
(Airfuge) method was adopted as described previously (Rivnay Band Metzger H, 1983) 
with some modifications (rotor type, speed, time and temperature). 
3.1.1. Gradient maintenance: 
To evaluate if our methodology would maintain the gradient pattern, sucrose 
gradients were prepared and run at the experimental conditions. As seen in Figure 5, the 
gradient was maintained in monotonic pattern whether the run time was 30 or 60 min. In 
30 min run, the recovered sucrose concentrations varied from 12% at the top fraction to 
23% at the bottom (Figure 5A) compared to 14% to 22% for one hour run (Figure 5B). 
The original gradient falls in the range of 5-30%. In addition, the average slope of the 
recovered gradient was only about one-half the original for Y2 hr run and one-third for 1 
hr run (slope values: original gradient 1.612 x 10·1, Y2 hr run 7.731 x 10·2, 1 hr run 5.146 
x 1 0"2). The reproducibility between duplicate tubes was excellent. In our study, we 
adopted the 1 hr protocol since sedimentation equilibrium is better attained with longer 
centrifugation times (Eikenberry EF, 1982). 
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Figure 5: Recovered gradients after centrifugation compared to the original sucrose 
gradient containing 50 ~1 30%, 10 ~1 25%, 30 ~I 20%, 45 ~1 10%, and 40 ~1 5%. (A) 
Gradient was run for Yz hr at room temperature at top speed. 25 f.tl fractions were 
collected from top to the bottom and translated to concentrations by measuring the 
refractive index. (B) Gradient was run for 1 hr at room temperature at top speed. 
Fractions were collected as for Yz hr run. ( • •) refers to the original gradient. 
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3.1.2. Liposomes/ peptide complex II airfugation: 
It is expected that unilamellar liposomes will float to the top of the tube after 
ultracentrifugation (liposomes flotation) while the free peptide (ligand) will migrate to 
the bottom (Dipali SR et al., 1996; Rivnay B and Metzger H, 1983; Huang A et al., 
1980). The first four fractions will be considered as the top of the tube while the last four 
as the bottom. In our study, almost 50% of the peptide adsorbed to the surface of the tube 
when peptide/ no liposomes was centrifuged. Thirty percent of the peptide was detected 
in the final four fractions (the bottom of the tube), leaving just 20% for the top fractions. 
In contrast, the addition of the peptide to the liposomes in the hydration step (i.e. 
liposomes/ peptide complex II) reduced the peptide adsorption to the surface of the tube 
to only 5%. Seventy five percent of the peptide floated to the top of the tubes suggesting 
successful association between the liposomes and the peptide. Figure 6 shows the 
patterns of the recovered peptide in both free peptide and liposomes/ peptide complex II. 
On the other hand, since cholesterol is one of the lipid components of liposomal 
formulations (50%), tracers of 3H-Chol was used to quantify and detect the phospholipids 
after centrifugation. It was found that 3H-Chol detection for liposomes/ peptide complex 
II revealed very close pattern to that observed with 125I detection (i.e. the incorporated 
peptide) (see Figure 7). These findings suggest that liposomes/ ligand association was 
almost complete when the peptide was added in the hydration step of liposomal 
preparation. 
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Figure 6: Airfuge flotation for liposomes-peptide complex II. 3H detection ( • ) 
representing liposomes in comparison to 1251 detection ( •) representing the peptide. 
Values were normalized as a percentage of the total radioactivity. Less than 1 % of 3H 
was detected in the empty tube compared to 5 % of the peptide. Each data point 
represents the average between duplicated tubes. 
25 
20 
ff. 15 ~ 
·s: 
:;::: 
u 
~ 
i 10 
a: 
5 
0 
1 2 
57 
3 4 5 6 7 8 
Fraction 
Figure 7: Airfuge flotation for liposomes-peptide complex II. 3H detection ( +) 
representing liposomes in comparison to 1251 detection ( •) representing the peptide. 
Values were normalized as a percentage of the total radioactivity. Less than 1 % of 3H 
was detected in the empty tube compared to 5 % of the peptide. Each data point 
represents the average between duplicated tubes. 
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3.1.3. Liposomes/ peptide complex I airfugation: 
The addition of the peptide in the final stage (i.e. after extrusion) resulted in very 
different patterns between the peptide and the associated liposomes after centrifugation. 
Figure 8 compares the patterns of 125I and 3H for liposomes/ peptide complex I. Twenty 
five percent of the peptide adhered to the tube surface while the remaining amount was 
equally divided between the top and the bottom fractions. It is important to notice that 
almost 20% of the peptide was recovered in fraction 7. These results revealed that more 
than 60% of the peptide was not associated with the liposomes. 3H detection for 
liposomes/ peptide complex I, however, revealed a pattern that is very close to both free 
liposomes and liposomes/ peptide complex II (refer to Figure 9). In the three conditions, 
more than 70% of liposomes floated to the top fractions. 
3.2. Cell Transfection: 
Transfection was executed on both rat MeA RH 7777 and human hep 3B cell 
lines. Both cell lines does not express the human wt p53 (Anderson SC et a/., 1998; 
Bressac B eta/., 1990; Puisieux A eta/., 1993). We used the newly developed lipospmal 
formula LPD that contains a polycationic peptide protamine (LiS eta/., 1998; Sorgi FL 
eta/., 1997; Gao X and Huang L, 1996). 
3.2.1. LPD/ peptide complex 1: 
As seen in Figure 10, transfection efficiency on MeA RH7777 cell line of LPD/ 
peptide complex I did not differ from that observed with LPD/ no peptide formula. 
Peptide amounts varied from 0.1 to 10 f.!g (e.g. 1 f..l.g DNA: 0.6 f..l.g protamine: 12 nmol 
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Figure 8: Airfuge flotation for liposomes-peptide complex I. 3H detection (•) 
representing liposomes in comparison to 1251 detection ( •) representing the peptide. 
Values were normalized as a percentage of the total radioactivity. Less than 1 % of 3H 
was detected in the empty tube compared to 25 % of the peptide. Each data point 
represents the average between duplicated tubes. 
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Figure 9: A comparison between liposomes flotation patterns eH detection) for different 
liposomal preparations: Liposomes no peptide ( • ), liposomes-peptide complex I (A), and 
liposomes-peptide complex II ( • ). Values were normalized as a percentage of the total 
radioactivity. Very close percentages of the recovered radioactivity were detected at the 
top and bottom fractions between various preparations. Each data point represents the 
average between duplicated tubes. 
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Figure 10: Transfection with LPD-peptide complex I on rat cell line MeA RH7777. 
Numbers refer to the amount of the included peptide in LPD formula. LPD labeling 
refers to no peptide treatment and DMSO labeling is the control (LPD+ DMSO). Fig. 
10 A and B correlates to two different experiments. Fig. 10 A: peptide amounts 
ranged from 0.1 to 1.5 Jlg. Fig. 10 B: peptide amounts ranged from 0.5 to 10 Jlg. 13 
Actin control bands were used to detect gel loading accuracy from lane to lane 
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Dotap: 0.1 Jlg peptide). It was also illustrated that the addition of DMSO in its highest 
concentration (i.e. 0.1 % V N) that corresponds to the addition of 10 Jlg of the peptide did 
not influence the transfection levels of the original LPD preparation. Despite that no 
increase in p53 expression was observed with LPD/ peptide complex I compared to LPD/ 
no peptide, a remarkable reduction in transfection efficiency was observed when the 
peptide ratio in the formula exceeded 6 Jlg (refer to Figure 1 0). These results showed that 
no targetability was observed when the peptide was added after the LPD preparation. 
These finding are in agreement with the minimal liposomes/ peptide association 
obtained when the peptide was incorporated into the liposomes after extrusion. 
3.2.2. LPD/ peptide complex II: 
The inclusion of the peptide in the hydration step of liposomal preparations (i.e. 
LPD/ peptide complex II) did not result in higher p53 expressions than those observed 
with LPD/ no peptide treatments. Figure 11 showed the results of experiments conducted 
on both human Hep 3B and rat MeA RH 7777 cell lines. In addition, the exclusion of 
protamine sulfate (considered as another variable in the formulation) did not affect the 
outcomes of the transfection. No increase in p53 expression was observed. DMSO 
volume in this experimental setting was 0.016% of the total volume of the transfecting 
medium. 
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Figure 11: Transfection with LPD-peptide complex II on human 
Hep 3B (Fig. 11 A) and rat MeA RH7777 (Fig. 11 B) cell lines. 
Labels: Lipop1ex (LD); Lipop1ex-peptide (LD-CS); Liposomes-
Protamine-DNA (LPD); LPD-peptide (LPD-CS). ~ Actin control 
bands were used to detect gel-loading accuracy from lane to lane. 
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3.3. Hemolytic activity: 
Hemolytic activity is an in vitro test used to evaluate the toxicity of the tested 
substance (Kobayashi S et al., 2001; Pape WJ, and Hoppe U 1987; Anderson RJ et al., 
1984). It relies on the ability of this material to destabilize the red blood cell membrane 
releasing its containment. Liposomes have been used as artificial biological membranes 
since their discovery in the early sixties (Bangham AD et al., 1965). Therefore, the 
hemolytic activity of the peptide on rat erythrocytes can provide some assessment of the 
potential destructive effects of the targeting ligand on liposomal membranous structures. 
Figure 12 shows the dose-response curve of peptide hemolytic activity. The 
peptide possesses mild hemolytic activity which increases in linear fashion with the 
increase of the peptide concentration. However, a peptide concentration higher or equal 
to 300 J.lg/ml (i.e. 107 J.lM) resulted in very close hemolytic activity values. The 
maximum hemolysis was in the range of30%. The best fit line of the data points showed 
a sigmoid pattern. There was, however, a strong linearity for concentrations <300 J.lg/ml 
(R2=0.9871) (by excluding the data point at the concentration of 400 J.lg/ml). The 
contribution of DMSO in the hemolytic assay was minimal (less than1.8 % in its highest 
contributions). 
In this study, the ratio between the lipids and the targeting ligand which resulted 
in lower transfection levels (Fig. 10 B) was 12nmol (DOTAP or Chol): 10 J.lg (peptide) or 
0.13 x 104 g (total lipids): 10 J.lg (peptide). On the other hand, lipids are the main 
component of the cell membrane. It has been shown that total lipids are 3.15 x 10-13 g I 
rat erythrocyte and it is composed of almost 70 % phospholipids, 25 % neutral lipids 
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Figure 12: Percent hemolysis versus peptide I concentrations. Dotted line 
represents the best fit line. Each data point is a mean of three measurements. 
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(mainly cholesterol) with the rest being glycolipids and ganglioside (Nelson GJ 1967). 
Therefore, the (total lipid: peptide) ratio was 3.15 x 104 g: 300- 400 J.tg (when the 
hemolytic activity reached its plateau) or 0.0787 x 104 g: 10 J.tg (corresponding to 400 J.tg 
peptide). This ratio is almost two times lower (in terms of the total lipids) than that used 
in liposomes/ peptide complex I preparations. It is thus expected that lipid bilayer 
destruction in liposomes might occur more efficiently resulting in liposomal fusion and 
subsequently lowering transfection efficiency. 
3.4. Particle size measurements: 
Particle size of liposomes can be indication of stability and transfection efficiency 
(Regelin AE et a/., 2000; Birchall JC et al., 2000; Ross PC and Hui SW 1999). The 
addition of the peptide after extrusion and the incubation for 20 min at room temperature 
resulted in significant increase (P<0.05) in the particle size only when the peptide amount 
was 10 J.tg. Liposomes: peptide ratios were consistent with tissue culture transfection 
experiment. Liposomal size increased by almost 35% from the original size. Figure 13 
shows the sizes of the liposomal preparations after the incubation with different amounts 
of peptide I. Usually the size of the liposomes falls in the range of 150-220 nm. 
In contrast, the addition of the peptide in the hydration step in a concentration of 1 
J.1g/J.1l did not affect the size of different liposomal preparations. Figure 14 illustrates the 
size of Liposomes, LPD, and lipoplex (i.e. no protamine) with and without the targeting 
ligand. In addition, the presence of 4% of DMSO in the hydration step does not affect 
the size of the liposomes (refer to Figure 14). Some LPD preparations were bigger than 
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Figure 13: Particle size measurements of liposomal preparations 
incubated with different amounts of peptide I. X-axis represents the 
amount of the peptide. Y -axis is the particle size of the preparation after 
20-min incubation with the peptide at room temperature. Each condition 
is a mean of five measurements. 
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Figure 14: Particle size measurements of different liposomal preparations in 
two conditions: no peptide ligand (empty bars) and with peptide ligand added 
in the hydration step of the preparation procedure (filled bars). DMSO 
labeling refers to the size of the original liposomes (empty bars) in 
comparison with liposomes hydrated with 4% DMSO solution. Each condition 
is a mean of five measurements. 
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Figure 15: LPD size before and after incubation with 10 J.lg peptide. 
Each condition is a mean of five measurements. 
200 
200 
-E 150 
s::: 
-:s 100 
t/) 
EO 
0 
0 5 11 40 
Figure 16: Particle size of liposomes stored at 4° C under argon 
atmosphere. No aggregates were observed within a month period. Each 
condition is a mean of five measurements. 
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expected (as large as lipoplex). The incubation of these LPD particles with 10 J.Lg ligand 
resulted in almost 100% increase in the size of the particles (see Figure 15). 
Since transfection experiments were conducted using freshly prepared liposomes, 
there was no need to check the effect of storage conditions ( 4 oc under argon atmosphere) 
on the sizes of the liposomes. In other experiments, however, liposomes were used 
within a month period from their preparation. No aggregates were observed during this 
period under the specified storage conditions (see Figure 16). 
3.5. Negative stain electron microscopy (EM): 
EM pictures showed similar liposomes and LPD particles to those reported by 
others (Li B et a/., 2000; Birchall JC et a/., 1999; Thierry AR et a/., 1997; Gao X et al., 
1996). Membranous structures with stained core region were very clear in all pictures. 
Spherical shapes were much more abundant than the tubular ones. In this method, the 
addition of the ligand did not result in any observed morphological changes. In addition 
to membranous structures, LPD pictures showed some condensed particles and bigger 
aggregates. More aggregation was observed in liposomal pictures. Figure 17 shows the 
different Electron micrographs for liposomes and LPD preparations. 
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Figure 17 A 
Figure 17 B 
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Figure 17 C 
Figure 17 D 
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Figure 17: Electron micrographs of ULV (A), ULV-peptide complex II (B), LPD (C), 
and LPD-peptide complex I (D). Arrows show particles with membranous structures. 
Head arrows indicate the larger aggregates. Peptide I was used for LPD-peptide and 
UL V -peptide complexes preparations. LPD-peptide complex 1: 1 J.Lg DNA: 0.6 J.Lg 
Protamine: 12 nmol Dotap: 1 J.Lg Peptide. 
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3.6. HepG2-liposomes interaction: 
One percent of 3H cholesterol was added to both liposomes and liposomes/ 
peptide complex II to assess the complexes' binding affinity to HepG2 cell membranes at 
4° C. Two different concentrations of the peptide were tested (0.5 lJ.g/lJ.l and 1 lJ.g/lJ.l). 
As seen in Figure 18, there was no increase in the binding affinity when the peptide was 
incorporated into the liposomes. HepG2-(liposomes/ peptide complex II) interaction 
profiles resembled that obtained with liposomes/ no peptide preparation 
3.7. Binding of the targeting ligand to HepG2 cells: 
It was reported that CS region II+ peptide inhibits the binding of CS protein to 
HepG2 cells by almost 90% (CeramiC et al., 1992; Sinnis Petal., 1994). In our study, 
the pretreatment with the cold peptide inhibited the binding of the 125I peptide by less 
than 35% with the highest concentrations. A T -test, however, showed that there was no 
significant difference between different conditions (P<0.05). Figure 19 summarizes the 
inhibition effects of different concentrations of the cold peptide on 125 I peptide binding. 
These results suggest that our peptide design and experimental conditions may have 
resulted in the loss of the original high binding affinity of region II+ peptide to hepatoma 
cells. 
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Figure 18: Comparison of the binding between liposomes and liposomes-
peptide complex II with Hep G2 cells. 100 nmol of 3H Liposomes were 
incubated at 4° C with HepG2 cells ( +) liposomes-no peptide (x) liposomes-
peptide complex II (0.5 Jlg/Jll) (•) liposomes-peptide complex II (1 Jlg/Jll). 
Each data point represents the mean of three measurements. 
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Figure 19: Binding of 1251 peptide ( 4J.tg) to HepG2 cells after 
preincuabation with different concentrations of cold peptide. 
Radioactivity was normalized to protein concentration in cell 
lysate. Peptide II was tested. 
77 
3.8. Mass spectroscopy: 
3.8.1. Electrospray (ES) Ionization: 
The ES ionization technique did not show the protonated molecular ion of the two 
peptides (expected by PeptideMass program (Wilkins MR et al., 1997): [M+Ht at m/z 
2804.4474 for peptide I and 2852.4685 for peptide II). However, we noticed the 
formation ofboth [M+2Ht2 and [M+3Ht3 • 
[M+2Ht2 (m/z 1401.83) and [M+3Ht3 (m/z 935.37) of peptide I are shown in 
Figure 20. Similarly, Peptide II ionization with [M+2Ht2 (m/z 1425) and [M+3Ht3 
(951) are shown in Figure 21. Ions were better formed when the sample was dissolved in 
50150 methanol/ dichloromethane rather than the aqueous solution containing 2% DMSO 
(see Figure 21). The strongest peak, however, for peptide II appeared at m/z 835.97. 
Tandem mass spectroscopy showed that the parent ion of 835.97 ion is [M+3Ht3 ion 
(refer to Figure 22). 
3.8.2. MALDI-TOF: 
This analysis was applied on peptide II. As seen in Figure 23, the protonated 
molecular ion [M+Ht appeared as expected at m/z 2853.4 which was not the major peak. 
The later peak appeared at m/z 2984.9, which differ by almost 131 Da from the expected 
protonated molecule of the peptide. This difference comes from TF A which has a 
molecular weight of 113 absorbing one H20 (i.e. 114+ 18= 132). Other peaks including a 
major peak appeared at 1680 does not relate to the original peptide and may represent 
impurities or degradation products. 
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Figure 20: Fragmentation pattern of peptide I using electrospray ionization method. 
M+2H and M+3H are shown on the spectra. The peptide was dissolved in 50/50 
methanol/ dichloromethan. 
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Figure 21: Fragmentation pattern of peptide II using electrospray ionization method. 
M+2H and M+3H are shown on the spectra. The peptide was dissolved either in dH20 
containing 2% DMSO (A) or 50150 methanol/ dichloromethan (B). 
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Figure 23: MALDI-TOF spectrum of peptide II. M+H ion appeared at rnlz 
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3.9. Theoretical hydrophobicity: 
Table 1 summarizes the hydrophobicity values of peptide segments: 
Region II+: EWSPCSVTCGNGIQVRIK 
Peptide I: YEWSPCSVTCGNGIQVRIKPGSAN 
Peptide II: NSLSTEWSPCSVTCGNGIQVRIKY 
Peptide\ hydrophobicity ccs Kyte-Doolittle 
Region II+ - 1.555 -0.116 
Peptide I -1.691 -0.329 
Peptide II -1.470 -0.225 
Eisenberg 
-0.126 
-0.117 
-0.127 
Table 1: Theoretical hydrophobicity of the peptide segments. Scales used were CCS, 
Kyte-Doolittle, and Eisenberg hydropathical scales. 
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4. Discussion 
The principle goal of this study was to develop a liver specific liposomal gene 
carrier that can deliver the apoptotic gene p53 efficiently to hepatic cells. Liver cancer 
treatment with p53 gene was chosen because it can eradicate hepatic cancerous cells 
effectively (Anderson SC et al., 1998), as well as enhance the efficacy of traditional 
therapies (Nishizaki M et al., 2001). Non viral gene carriers are less efficient than the 
viral vectors. This limitation was, however, counterbalanced with safety (especially low 
immunogenicity), simplicity of preparation, and high gene encapsulation capability in 
comparison with viral vectors (Cusack JC Jr, and Tanabe KK 2002). Modifications to 
improve the efficiency of non-viral vectors including liposomal preparations are currently 
under intense research. 
A good liposomal formulation for cancer gene therapy should encapsulate and 
protect the nucleic acid materials, escape the endosomal degradation and reach 
specifically to the tumor site. The last goal can be achieved by incorporating a tumor 
specific ligand which can deliver DNA specifically to the cancerous tissue. In the case of 
hepatocyte cells, the main challenge is to divert the liposomes from the lung ''trap". 
Conventionalliposomes (lyer Metal., 2002; McLean JW et al., 1997; Osaka G et al., 
1996) and LPD (Ma Z et al., 2002; LiB et al., 2000; LiS and Huang L 1997) tend to be 
trapped by capillary embolism in the lungs where transfection occurred mainly. Liver 
accumulation of lipoplexes can be enhanced through manipulations of the particle size 
(Hwang SH et al., 2001; Alino SF et al., 1996; Wu J, and Zem MA 1996) or lowering the 
complex surface charge (Mahato RI et al., 1998). More recently, transfection occurred 
mainly in the liver with the development of the serum resistance poly( cationic lipid) (Liu 
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L et a/., 2003). It is also shown that significant amount of LPD accumulates in the liver 
(LiS eta/., 1998; LiS and Huang L 1997). 
In liver uptake, it is essential to ensure that liposomes have actually reached the 
parenchymal liver cells rather than the phagocytic kupffer cells. Some studies have 
shown that kupffer cells were actually the main destination for liposomes in the liver 
(Litzinger DC eta/., 1996; Roerdink F eta/., 1981). This is less of a problem when 
receptor specific ligand is attached to the surface of the liposomes. The ligand will bind 
to its receptors on the parenchymal cells before internalization occurs. 
Malaria region II+ peptide of CS protein is an attractive liver ligand since its 
specific binding to heparan sulfate proteoglycans receptors is essential to successful CS 
protein binding to the cell membranes and substantial malaria parasite invasion into the 
liver. It has been illustrated that CS-poly (L-lysine) conjugate successfully targeted 
recombinant DNA to liver cultures (Ding Z et al., 1995). In this study, we explored the 
possibility of utilizing region II+ peptide for cationic liposomal liver targeting. A lipid 
moiety was introduced to the N-terminus of the peptide to be anchored within the lipid 
bilayers of the liposomes. This strategy for developing liver-targeted liposomes was 
successfully used for antibodies (Harsch M et al., 1981; Huang A et a/., 1980), 
glycoproteins (Hara T et al., 1995; Tsuchiya Set a/., 1986) and glycopeptides (Kallinteri 
P et al., 2001). The main advantage in this strategy is the ease of ligand incorporation 
(simple incubation) and the reduction of materials used. Two forms of the modified 
peptide were used as discussed in the introduction. Peptide I was linked to a palmitic 
acid chain while peptide II was linked to a myristic acid chain. Both peptides have 
extension of five amino acids derived from the original sequence of malaria CS protein. 
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The extension was, however, in the C-terminus of peptide I versus the N-terminus of 
peptide II. Based on the dates when the modified region II+ peptides were synthesized, 
all the experiments except the binding studies were performed on peptide I. Since both 
peptide I and II contain region II+ peptide motif and were modified in a very similar 
fashion, it is expected that the general behavior of these peptides will be similar. 
4.1. Peptide solubility: 
The peptides (with no modifications) exhibit a hydrophilic nature as calculated by 
Kyte-Doolittle (Kyte J and Doolittle RF 1982), Eisenberg (Eisenberg D et al., 1982), and 
CVS (Tossi A et al., 2002) hydropathical scales. The mean theoretical hydrophobicity 
for peptide segments were shown in table 1. All the predicted measurements exhibited 
slightly negative values (i.e. more hydrophilic). These results are in agreement with 
previous studies on this malaria peptide in which aqueous media were used to dissolve 
the peptide and other motifs from its sequence (Chatterjee S et al., 1995; Sinnis P et al., 
1994; Cerami C et al., 1992). Peptides I and II (without the fatty acid linkage) were 
slightly more hydrophilic than the original region II+ segment. Our aim was that the 
attachment of the fatty acid chain will enable us to dissolve the peptide in an organic 
solvent that can be added to lipid mixture such as methanol or chlorophorm. 
Our modified forms of the peptide, however, were only soluble in DMSO. 
DMSO brought the peptides into aqueous solutions such that the final concentration of 
DMSO did not exceed 2%. All other common organic solvents including methanol, 
ethanol, chloroform, acetonitrile, and dimethyl sulfoxide (DMF) did not dissolve the 
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peptides. Particulates were observed with the naked eye. The only exception was DMF 
in which aggregates were observed after microscopic examination. 
4.2. Liposomes/ peptide complex formation: 
Both size exclusion chromatography and ultracentrifugation can be used to 
separate liposomes, free ligand and liposomeslligand complex from each other. The main 
obstacle to apply either of these techniques is the small volume of the samples in our 
study (in the range of microliters). Therefore, an air driven ultracentrifuge (Airfuge) was 
used. This technique was utilized before for liposome-related separation evaluation 
(Rivnay Band Metzger H, 1983). 
Free liposomes float to the top of the tube (Fig. 9), while free peptide was 
concentrated at the bottom of the tube, as well as adsorb to its surface (Fig. 6). We have 
shown here, through liposome flotation experiments that complete liposomes/ ligand 
association was achieved when the peptide was added during the hydration step of 
liposomal preparations (liposomes-peptide complex II). In this complex, the peptide 
floats to the top in a similar manner to that obtained with the associated liposomes (Fig. 
7). On the other hand, the association was less than 40% when the peptide was incubated 
with unilamellar liposomes after extrusion (Fig. 8). This association is minimal since 20 
% of the free peptide (i.e. no liposomes) was normally detected at the top fractions after 
ultracentrifugation (refer to Fig 6). 
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4.3. LPD preparation: 
We choose to use the novel LPD preparation because of its high efficiency 
compared to conventionalliposomes (LiS eta/., 1998; Sorgi FLeta!., 1997; Gao X and 
Huang L 1996). LPD utilizes protamine to condense nucleic acid before being 
complexed with the lipid vesicles. For liver targeting purposes, LPD was recently coated 
with the targeting ligand asialofetuin through charge-charge interactions, which 
significantly increases HepG2 cells uptake of the encapsulated DNA (Arangoa MA et a/., 
2003). 
LPD mean particle size is usually in the range of 100-250 nm as reported by 
others (Ueno NT et a/., 2002; Sorgi FL et a/., 1997). Our LPD particle size was, 
however, in the range of 100-350 nm and varied from batch to batch. Some LPD 
formulations have a larger particle size than expected, almost similar to that obtained 
when protamine is excluded (i.e. lipoplexes). This inconsistency in the particle size 
measurements is due to the existence of salts as our DNA was stored in TE buffer (Tris-
HC110 mM, EDTA 1 mM, pH 8.0) as provided by collaborators. Salts can interfere with 
the charge-charge interactions between LPD ingredients causing the observed 
inconsistent LPD size measurements (Tan Y et a/., 2002). Therefore, it is essential to 
exclude any salts from the formulation in any future work. LPD is also naturally 
composed of heterogeneous particles of free liposomes, lipoplex and LPD (Li S et a/., 
1998). This heterogeneous mixture in terms of different sizes was observed in our 
preparations by EM picture (Figs. 17C and 17 D). Sample preparation for EM analysis, 
however, included air drying which might lead to liposomal aggregation. These 
aggregates were observed in ULV preparations (see Figs. 17 A and 17 B). 
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4.4. LPD transfection and liposomes/ HepG2 binding: 
Based on liposomes/ ligand association experiments, it is expected that LPD or 
lipoplex mediated p53 delivery to hepatoma cells will be better achieved with liposomes-
peptide complex II. In our study, p53 expressions were at the same levels for all the 
tested formulations. Western blotting analysis is illustrated in Figs 10 and 11. It was, 
however, observed that the transfection level was significantly reduced when more that 6 
f.lg peptide was incubated with LPD preparation as shown in Fig 10 B. Monitoring 
liposomal stability through particle size measurements and assessing the hemolytic 
activity of the peptide provided some explanation for this observation. 
Size increases in both liposomes and LPD were observed when liposomal 
formulations were incubated with high concentration of the peptide. The size of the free 
liposomes was significantly increased more than one third of the original formulation 
(Fig 13) while the LPD size was doubled (Fig 15). Particle size is a critical factor in 
liposomal transfection efficiency (Almofti MR et al., 2003a; Ross PC, and Hui SW 
1999). It has been demonstrated that the size increase of the LPD formulation will reduce 
the ability of the complex to deliver the encapsulated DNA to cultured cells (Li B et al., 
2000). Since our LPD size was increased by almost 100%, this may explain the observed 
reduction in LPD mediated gene transfer when more than 6 f.lg peptide were used for 
LPD-peptide complex I formation. This conclusion is in agreement with the mild 
hemolytic activity possessed by the peptide (Fig. 12). On the other hand, the addition of 
the peptide in the hydration step (which was 0.8 peptide: 12 nmol DOTAP) did not 
influence liposomes stability as monitored by particle size analysis illustrated in Fig. 14. 
It seems that the peptide can destabilize the membrane lipid bilayers in both the 
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liposomes and red blood cell membranes. This will facilitate fusion among the liposomal 
particles resulting in aggregation and consequent reduction of transfection. 
To mimic region II+ peptide in the malaria parasite, the peptide should, however, 
exist in close proximity on the surface of the liposomes. It has been shown that region 
II+/ receptor interactions involves more than one peptide segment (Sinnis P et al., 1994; 
Cerami C et al., 1992). It is possible that the limitation we encountered in terms of the 
total peptide added (because of both DMSO and the destruction ability of region II + on 
the lipid bilayers) may have prevented sufficient coating on the liposomal surface. 
In addition to the non-targetability observed with the transfection experiments, 
liposomes-peptide complex IV HepG2 interactions resulted in no increase in liposomal 
binding to the cell surface as measured by 3H-Chol detection in comparison with 
liposomes/ no peptide preparation (refer to Fig. 18). 
These findings suggest that the targeting ligand might have been oriented inwards 
from the liposomal surface or buried within the lipid bilayers. It has been shown, 
however, that different ligands, linked to a hydrophobic moiety, were oriented to a large 
extent to the outer side of the liposomes (Kallinteri P et al., 2001; Zalipsky S eta/., 1997; 
Tsuchiya S et a/., 1986; Huang A et a/., 1980). Therefore, it is expected that our ligand 
will be aligned in the same fashion within the lipid bilayers. This assumption needs to be 
explored in any future investigation. 
On the other hand, it is also possible that our methodology resulted in the loss of 
the peptide binding specificity to its receptors on the liver cells. While in previous 
studies the pretreatment of fixed HepG2 cells with region II+ peptide resulted in almost 
complete inhibition of the binding of the CS protein to these cells (Sinnis P et a/., 1994; 
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Cerami C et al., 1992), our modified region II+ peptide pretreatment to HepG2 cells 
inhibited the binding of 1251 peptide by only 30%. This inhibition was, however, 
statistically insignificant in comparison with no pretreatment control (Fig. 19). This 
finding confirmed our assumption for the loss of the peptide binding specificity. One 
possibility is that oxidation mediated by DMSO occurred during peptide solution storage. 
DMSO has destructive effects on many amino acids (Spencer RL, and Wold F, 1969) 
such as tryptophan and cysteine which exist in the peptide sequence. Oxidation by 
DMSO will alter the peptide properties including its liver-specificity. This may explain 
the non-targatability observed in our methodology. Despite the serious potential of the 
oxidation problem especially with cysteine moieties that are prone to air oxidation, MS 
analysis by both ES and MALDI-TOF techniques showed spectrum peaks related to the 
molecular ion (rnlz 2804.4 peptide I and 2852.4 Peptide II). Non related peaks are 
mainly due to the impurities since peptide purity was 80%. MS spectrums as obtained 
from the working solution are illustrated in Figs. 21, 22, and 23. 
On the other hand, it is possible that conformational changes have occurred in the 
peptide after modification and dissolving in 2% DMSO aqueous solution. Circular 
dichroism (CD) analysis can provide information on the secondary structure (2D 
structure) of peptides and proteins (Venyaminov SY and Yang JT 1996). Structural 
analysis of peptide segments of CS protein including region II + were previously 
analyzed by this technique (Roggero MA eta/., 1995; Verdini AS et al., 1991). We 
were, however, unable to load the modified peptide into the CD cell (Jasco J-810, Easton, 
MD USA) without the formation of air bubbles. Bubbling prevented us from performing 
this essential analysis. 
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The nuclear magnetic resonance spectroscopy technique (NOESY NMR) can also 
provide some insight into the possible conformational changes (Skelton NJ and Chain WJ 
2000). These tests should be considered for any future work with region II+ peptide 
designed for liver specific targeting. 
4.5. Future directions: 
Despite the well documented evidence for region II+ specificity towards liver 
cells (Ying Pet a/., 1997; Chatterjee Set a/., 1995; Aley SB eta/., 1986), our chemically-
modified version of the peptide, as well the liposome-peptide complexes lack this 
specificity. The main problem with our peptide was its poor solubility. DMSO was the 
only solvent that dissolved the peptide and brought it into aqueous media. DMSO is not 
the solvent of choice for peptides and proteins. In addition, it has toxic effects on living 
tissues whether cultured cells in vitro or animal models in vivo. Therefore, any future 
modifications should consider increasing the aqueous solubility of the peptide or at least 
have better range of solvent choice. One simple modification is the inclusion of some 
hydrophilic amino acids at theN-terminus of the peptide. A repeat of (Asn-Gln) 3( which 
will not contribute to the peptide net charge), for example, will elevate the theoretical 
hydrophobicity of the peptide segment almost two times as predicted by the 
hydrophobicity scales ( CSS -2.59; Kyte-Doo/ittle -0.976; Eisenberg -0.2496). In 
addition, these peptides might serve as a spacer from the lipid layers. 
More efficient modification might be the usage of PEG linkage between the lipid 
part and the ligand. This approach is widely used especially for mAb (Bendas G 2001). 
In a recent study, a peptide ligand (specific to restenosis-involved cells) was linked to the 
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lipid through PEG 3400. The lipid-PEG-ligand conjugate was added to the lipid mixture 
in the first stage of liposome preparation (Lestini BJ et al., 2002). In a similar manner, 
we can link the region II+ peptide with palmotic acid for instance. One of the most 
widely used PEG as a linkage for targeting ligands is PEG 2000 (!den DL, and Allen TM 
2001; ShiN, and Pardridge WM 2000; Bendas Get al., 1999; Huwyler Jet al., 1996). 
This linkage will increase the water solubility as PEG-linked compounds are more 
hydrophilic than the original-no PEG molecules (Katre NV et al., 1987; Chen RH et al., 
1981). In addition, a reasonably long spacer (in comparison with peptide linkages) will 
be provided through the PEG portion. It has been shown that longer spacers will result in 
better targeting than short spacers on the liposomal surface (Zhou W et al., 2002; 
Kawakami S et al., 1998). The peptide will contain tyrosine moiety at its C-terminus for 
radio-labeling. The possibility of disulfide linkages between two moieties of the 
modified peptide also need to be explored since such modification will create the 
necessary multi region II+ required for peptide receptor interactions (Sinnis P et al., 
1994; Cerami C et al., 1992). Figure 24 shows the proposed modifications for region II+ 
peptide as a liver targeting ligand. 
Palmitic Acid 
Palmitic Acid 
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Region II + peptide 
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H2 H2 
PEG 2000 
Region II + peptide 
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H2 H2 I I 
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Figure 24: Schematic representation for region II+ peptide as liver targeting ligand to be 
anchored within the lipid membranes of cationic liposomes. 
The sequence of the investigation will follow the following order: 
4.5.1. The evaluation of the binding affinity of the peptide to hepatoma cells and 
generation of binding curve: 
Binding dissociation equilibrium constant (KQ) and maximum receptor 
number/cell (Bmax) can be calculated. This calculation was not possible in our study 
because of the existence of DMSO which can lead to cell death in high concentrations 
required for competition study. Kt Value will be compared with the non-modified 
peptide. It is possible that pegylated compounds will have lower affinity toward their 
receptors in vitro in comparison with the non-modified molecule. This relationship is 
reversed in vivo where the retarded renal clearance and the long half life in the blood 
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stream will increase the binding of the pegylated substances to their receptors (Bailon P 
and Berthold W 1998). 
4.5.2. The formation of cationic liposomes/ ligand complex: 
Peptides can be added at the hydration step or after extrusion. In spite that our 
study has shown that liposomes/ peptide complex was better formed if the addition was 
performed at the hydration step of liposomal preparation, the addition of the peptide after 
extrusion will ensure that the ligand is oriented outside (Zalipsky S et al., 1997). It has 
been shown that this can be facilitated through mild heat (Zalipsky S et al., 1997). In 
addition, Incubation time can play a role in the complex formation. The usage of low 
concentrations of sodium cholate or deoxycholate, mild detergents, was used to enhance 
the formation of liposomes/ ligand complexes (Kallinteri P et al., 2001; Hara T et al., 
1995; Huang A et al., 1980). These detergents can· adsorb to and solubilize the lipid 
membrane forming a transient pores within the membranous structure (de Ia Maza A and 
Parra JL 1997; Schubert R et al., 1986) such that the ligand is readily available to be 
incorporated within the lipid bilayers. It was reported that liposomes/ mAb (linked to 
palmitate) conjugate was not assembled when Na deoxycholate was excluded from the 
preparation (Shen DF et al., 1982). Newly developed post insertion technique can also 
be evaluated. It was recently applied successfully for hexapeptide linked to DSPE 
(distearoylphatidyl ethanolamine) through PEG 2000 linkage (Moreira JN et al., 2002). 
Free ligand can then be separated from the complex by ultracentrifugation, column 
chromatography or dialysis. All these factors need to be explored and optimized. 
The evaluation of liposomes/ HepG2 interactions can be improved (over the 
methodology we adopted in this study) through the usage of 3H-CHE (Cholesterol [1,2-
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3H -(N}]-hexadecyl ether) as a radiolabel tracer. 3H CHE does not exchange with cell 
membranes after internalization. Therefore, valuable information about cell uptake can 
be obtained. In our study, binding (which is the first step for internalization) was 
evaluated at 4 C since 3H-Chol can be exchanged with the cell membranes at 37 C (i.e. 
after internalization). Another membrane non-exchangeable lipid radioactive marker is 
14C Chol-oleate (Kirby C, and Gregoriadis G 1980). Fluorescent lipid markers are also 
available such as NBD-Chol (7-nitrobenz-2-oxa-1,3-diazol-4-yl-labeled. Cholesterol) 
(Mukherjee S. and Chattopadhyay A 1996). 
In addition, competition experiment with free peptide (lab led liposomes incubated 
with HepG2 cells in the presence of free peptide) will confirm the efficiency of this 
methodology of complex formation. 
4.5.3. Transfection experiments: 
Transfection experiments with LPD and lipoplexes bearing the p53 gene can then 
be evaluated in cultured cells (Hep3B and MeA RH 7777). p53 therapeutic effects 
includes apoptosis induction and cell cycle arrest (Zou Y eta/., 1998). 
4.5.4. In vivo evaluation: 
In vivo evaluation can be applied on mice or rats bearing liver cancer lesions 
through tail vein or intra-arterial injection of the liposomal formulation. It has been 
shown the transfection efficacy in the liver can be elevated through hepatic artery 
delivery (Seol JG eta/., 2000; Anderson SC eta/., 1998). Therapeutic effects such as 
tumor size and animal life span can then be evaluated and compared with LPD- no 
peptide treatment. 
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4.6. Closing remarks: 
CS protein derived liver targeted ligands is an attractive option for developing 
liver specific liposomal formulations. Highly hepatic-specific, revolutionary conserved 
region I and region II+ peptides of the malaria CS protein are possible candidates as 
targeting moieties. Despite that our liposomes/ region II+ complexes did not show the 
expected targeting effects, alternative ligand modifications and complex preparation 
methods (that may overcome the obstacles experienced with this study) are currently 
under experimental design and evaluation. 
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